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The incidence of cancer in children < 16 year is one per 10.000. In the 
Netherlands 350-400 new cases are diagnosed annually. Acute Lymphoblastic Leukemia 
(ALL) is one of the most common malignancies in children. Out of 350-400 patients with 
childhood cancer approximately 80 patients are diagnosed to have ALL.
Since the introduction of central nervous system (CNS) prophylaxis and the development of 
more intensive chemotherapeutic regimens, the overall event free survival rate in ALL 
improved from 4% in 1972-1973 to 66% in 1988-1991 147. Therefore it is important to pay 
attention to the late sequelae of therapy.
Growth retardation is a well-known side-effect in children treated for ALL 17,27,36,79,126,131,156. 
The causal factors for disturbed growth in these patients can be: the disease itself, the 
treatment modalities: chemotherapy, radiotherapy and corticosteroids and loss of weight 
due to illness or treatment. Especially cranial irradiation (CI) as CNS prophylaxis has been 
associated with a significant loss of standard deviation score (SDS) for height at final height 
67,120,127. About the influence on height at final height, of treatment without CI, conflicting 
results have been published. Holm et al 60 reported about normal final height of these 
patients while in another study significant decrease in final height was noticed 127.
1.2 Acute Lymphoblastic Leukemia
1.2.1 Disease characteristics o f ALL
Acute lymphoblastic leukemia (ALL) is a disorder characterized by the 
uncontrolled growth and proliferation of immature lymphoid cells. The signs and symptoms 
of the child presenting with ALL reflect the degree of bone marrow infiltration with 
leukemic cells and the extent of extramedullary disease spread.
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In the pathogenesis of ALL genetic factors are presumed to play a significant role 101. 
Evidence for this relationship is based on several observations including the association 
between various constitutional chromosomal abnormalities and childhood ALL, the 
occurrence of familial leukemia, the high incidence of leukemia in identical twins and the 
demonstration of karyotypic abnormalities in leukemic cells of children with this disease. In 
addition to genetics environmental factors, viral infection and immunodeficiency may 
predispose to leukemia 101.
Morphologic, immunologic, cytogenetic and biochemical characterizations of leukemic 
lymphoblasts have confirmed that ALL is a biological heterogeneous disorder. The 
heterogeneity reflects the fact that the leukemia may develop at any point during the 
multiple stages of normal lymphoid differentiation.
Although ALL can occur at any age, the peak incidence of ALL occurs at approximately 4 
years of age.
1.2.2 Treatment o f ALL
Without effective antileukemic therapy, ALL is an uniformly fatal disease. The 
recognition that ALL is a heterogeneous disease and that children can be stratified into 
various risk groups has profoundly influenced therapy. Modern ALL treatment regimens 
divide therapy into four main treatment elements: remission induction, central nervous 
system preventive therapy, consolidation and maintenance therapy.
In the treatment of ALL, combination chemotherapy is the primary therapeutic modality.
In the Netherlands, children with ALL are treated according to the protocols of the Dutch 
Childhood Leukemia Study Group (DCLSG) since 1972. In the period of 1972-1995 the 
DCLSG has implemented eight protocols for the treatment of childhood acute 
lymphoblastic leukemia.
Protocol 1 represented a non-invasive treatment protocol 147.
The protocols 2 to 6 (1973-1988) were based on Pinkel's principe of "Total Therapy” 100. 
Pinkel layed the foundation of the current treatment strategy for childhood ALL. He was 
the first to design a treatment protocol which turned out to be curative for patients with
15
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ALL. The general procedure of Pinkel consisted of 1. remission-induction therapy with 
multiple antimetabolite chemotherapy and prednisone, 2. prophylactic central nervous 
system therapy with cranial irradiation and intrathecal methotrexate, early during complete 
remission, to eliminate residual leukemic cells in the central nervous system and 3. 
continuation chemotherapy, consisting of simultaneously administered multiple drugs for 2 
to 3 years to eradicate all remaining leukemic cells 100.
Cranial irradiation has been associated with late sequelae, notably with neuropsychologic 
dysfunction and growth retardation 66,91,106,131 and has therefore, since 1984, been omitted 
from the Dutch protocols.
The protocols 7 and 8 (1988-1995) were developed after the German Berlin-Frankfurt- 
Münster (BFM) group 54. In these protocols patients were no longer treated on a uniform or 
standard treatment regimen but patients were assigned into different risk groups on the 
basis of prognostic factors, stratifying treatment according to the prognostic factors.
1.2.3 Nutritional state
Both ALL as a serious illness and the treatment modalities applied in the treatment 
for ALL can have a negative influence on the appetite of the patients leading to a bad 
nutritional state. Bad nutrition followed by loss of weight can affect growth 4.
1.3 Human growth
1.3.1 Introduction
Height is a strongly genetically determined characteristic and under favourable 
conditions a child will growth according to a predominated growth curve 4. Under normal 
conditions, parental heights can give a good indication of the target height to which a child 
is aiming. Tanner described growth as a target-seeking function 136 and he postulated that 
growth is controlled by a central regulator which senses body size to a setpoint for target 
size and accelerates or decelerates growth rate accordingly. Measurement of growth is 
important for monitoring the health of a child. In children with ALL both the disease and
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the treatment can have an influence on growth. These environmental influences on the 
growth process are at their maximum when growth is at its fastest.
In childhood three principal phases of growth can be distinguished: 1. the rapid and rapidly 
decelerating growth of infancy, representing the last phase of fetal growth, 2. the steady 
and slowly decelerating growth of midchildhood and 3. growth of puberty 56,63. Growth 
during infancy is regulated principally by nutrition and local growth factors, while growth 
during childhood is largely determined by growth hormone (GH) secretion and thyroid 
hormones. Growth during puberty is beside growth hormone and thyroid hormones also 
endocrinological dependent of sex steroids. The sex steroids have a direct anabolic action 
and a modulating effect on GH secretion 56. A clear rise in GH secretion occurs during 
puberty.
1.3.2 The growth plate
Growth of the long bones is a remarkable integrated process with a coordinated 
interaction of systemic and local factors in the developmental process. Elongation of bones 
proceeds by endochondral ossification, whereby a cartilaginous growth plate moves 
progressively distal from the diaphyseal centre, leaving a front of newly ossified bone. 
Control of the pace of the growth process is largely an endocrine phenomenon, while local 
control by paracrine and autocrine factors is essential to coordinate cellular and matrix
events 23 , 99,153 (figure 1.1).




The principle hormone influencing midchildhood growth is growth hormone (GH). 
GH secretion occurs in a pulsatile fashion. The secretion of GH is regulated by 
neurotransmitters and by hormonal and metabolic substrates 35 (figure 1.2).
The final common pathway for integration of these signals involves two hypothalamic 
neuropeptides; growth hormone releasing hormone (GHRH) and somatostatin (SS). GHRH 
controls synthesis and release of GH, while SS modulates its pulsatile secretion 56.
Secretion of GH results in production of IGF-1 especially by the liver. The regulation of
Figure 1.2: The general pattern of endocrine regulation of growth.
(GHRH: growth hormone releasing hormone, SS: somatostatin, GH: growth hormone, IGF-1: 
insulin-like growth factor 1).
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GH release is also influenced by the production of IGF. IGF-1 inhibits basal GH gene 
transcription, suggesting a feedback role for IGF-1 in GH regulation 154. The somatotroph 
populations of the pituitary are differentially responsive to IGF-1 and SS. SS is a much 
more effective inhibitor of total GH release than IGF-1 and appears to affect most, if not 
all, somatotrophs 58. At the cellular level it would appear that IGF-1 inhibits only the 
secretion of newly synthesized GH, while SS inhibits both stored and newly synthesized 
GH pools 124.
Secretion of GHRH is also inhibited by IGF-1 in vitro 125. GH regulation is largely 
dependent on GHRH/SS equilibrium and probably controlled by GH and IGF-1 forming 
systemic and local feedback loops (figure 1.3).
The human growth hormone (hGH) gene is present on the long arm of chromosome 17 and 
is part of the hGH gene cluster which consists of five very similar genes 56. Transcription 
of the hGH1 gene leads to the synthesis of hGH a protein with a molecular weight of 22 
kD, which accounts for 90% of the GH synthesized. The excision of the second intron of 
the hGH1 gene leads to an alternative splicing site. This alternative splicing forms the basis 
of the 20 kD variant of hGH which comprises 5-10% of total pituitary hGH 76. The two 
forms are co-secreted and similar forms are observed in the plasma with the 22 kD form 
predominant at 75%, the 20kD variant 20% and acidic hGH 5%. The molecular forms of 
hGH secreted in vivo are independent of the secretory stimuli applied to the somatotroph. 
GHRH, exercise and sleep related GH-secretory bursts all produce the GH forms: 22 kD, 
20 kD and acidic GH 12.
1.3.4 Growth hormone binding protein
In plasma, large forms of GH can be detected with molecular weights in the order 
of 40-70 kD 56, representing the interaction of GH with a circulating protein 10. This high- 
affinity, low capacity binding protein for hGH represents the extracellular portion of the 
monomeric GH receptor 11. It has more affinity for the 22 kD form than for the 20 kD 
variant and approximately 50% of circulating 22 kD hGH is estimated to be in a complexed 
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Figure 1.3: Pituitary GH release as a net result of an intricate interplay between two hypothalamic 
hormones, the stimulatory GH-releasing hormone (GHRH) and its inhibitory counterpart 
somatostatin (SS). The stimulating effect of GHRH does not occur before the concentration of SS, 
in the hypophyseal portal level, is low.
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important effect on the in vivo kinetics of GH, prolonging the biological persistence of GH 
in vivo.
The pattern of secretion of GH may play an important role in the control of body 
growth. The rapid changes in circulating GH levels require efficient adaptation of the 
somatogenic receptors to induce the specific signals necessary to promote growth. It has 
been speculated that the low basal level of GH between pulses is important in that it allows 
receptor recovery 96. The rapid changes in GH secretion must be reconciled with the 
buffering effect of two factors: the presence of near constant circulating levels of IGF-1 
bound to specific IGF-binding proteins and the fairly well-conserved levels of GH-binding 
protein in physiological and pathological conditions.
The effect of GH on the growth plate, to effect growth, is complex. It is thought that GH 
acts on growth via a dual mechanism (figure 1.4):
- A direct stimulation through specific receptors on growth plate 
chondrocytes 150.
- An indirect action through insulin like growth factor-1 (IGF-1) 2339.
1.3.5 The insulin-like growth factors
There are 2 insulin-like growth factors of which at least one (IGF-1) is GH 
dependent. These peptide factors mediate many of the anabolic and mitogenic actions of 
GH. The IGF's were so named because of their evolutionary and structural relationship 
with proinsulin. The diverse actions of the factors include:
- Stimulation of DNA synthesis and cell multiplication.
- Promotion of the incorporation of sulphate into cartilage.
- Insulin-like activity in extraskeletal tissues for instance lipolyse.
IGF-1 is a basic peptide of 70 amino acids and IGF-2 is a slightly acidic peptide of 67
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Figure 1.4: The effect of growth hormone on the epiphyseal growth plate.
- GH stimulates precursor cells.
- Differentiating cells become IGF-1 responsive.
- The gene encoding for IGF-1 is expressed in these cells, resulting in increased 
local synthesis of IGF-1.
- Locally produced IGF-1 acts by autocrine and paracrine mechanisms.
- The local IGF-1 production controls cell multiplication and differentiation.
amino acids. The human IGF-1 gene spans approximately 95 kb of genomic DNA on the 
long arm of chomosome 12 142. The human IGF-2 gene is located on the short arm of 
chromosome 11, immediatly adjacent to the insulin gene and spans 35 kb of genomic DNA 
14. Complex control of IGF gene expression contributes to variability in tissue expression 
21110. The liver is a major site of IGF production and is the main contributor to the 
circulating pool of IGF-1. However many other cells and tissues produce IGF-1 62. Locally 
produced IGF-1, stimulated by GH, acts via an autocrine/paracrine mechanism probably 
distinct from the endocrine circulating IGF-1.
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IGF-1 is considered an important postnatal growth factor because of rising levels at term in 
humans. IGF-2 has been regarded as an essential fetal growth factor as it is expressed in 
diverse tissues throughout gestation, however serum IGF-2 levels remain significant and 
constant during the human lifespan 113. The postnatal role of IGF-2 in humans is 
unresolved. Expression of IGF-2 messenger RNA has been demonstrated in diverse 
primary tumours and malignant cell lines, including many sarcomas, Wilms'tumor, 
phaeochromocytoma, neuroblastoma and hepatoblastoma 32 107. Investigators speculate that 
tumor growth is stimulated by IGF-2 autocrien action 33.
In the human foetus serum IGF-1 levels increase with gestational age 15. IGF-1 levels in 
human newborn serum are generally 30-50% of adult levels. Serum concentrations rise 
gradually during childhood attaining adult levels by the onset of sexual maturation 680. 
During puberty IGF-1 concentration rise to levels 2-3 times those seen in adults 115. 
Accordingly IGF-1 levels during adolescence correlate better with stages of puberty than 
with chronological age.
From findings that patients with GH receptor defects show a pubertal rise in serum IGF-1 
despite a decline in GH levels it has been concluded that there is a direct effect of sex 
steroids upon IGF-1 144. Serum IGF-1 levels demonstrate a progressive age-associated 
decline in adults 116.
Serum IGF-2 levels do not follow the developmental pattern of IGF-1 levels. Human 
newborn concentrations of IGF-2 are approximately 50% of adult levels. Adult 
concentrations are attained by 1 year of age without the marked pubertal rise seen with 
IGF-1. There is little, if any, subsequent decline.
1.3.6 IGF-receptors
The IGF's can bind with low affinity to insulin receptors but two distinct IGF 
receptors are discriminated 24,65. The type-1 IGF receptor is capable of binding both IGF-1 
and IGF-2 with high affinity. The type-2 IGF receptor is entirely distinct from the insulin 
and type-1 IGF receptors and bears no structural similarity to them.
Studies have indicated that the classic mitogenic and metabolic actions of both IGF-1 and
23
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IGF-2 are mediated through the type-1 IGF receptor 28,40. Several experimental observations 
provide evidence for IGF-2 actions mediated by the IGF-2 receptor. Minniti et al 86 
reported that IGF-2 appears capable of acting as an autocrine growth factor for human 
rhabdomyosarcoma cells, actions apparently mediated through the type-2 receptor. This 
study provides a potential mechanism for signal transduction through the type-2 IGF 
receptor, but it is still generally assumed that most actions of IGF-2 are mediated by the 
type-1 IGF receptor.
1.3.7 IGF-binding proteins (IGFBP 's)
The IGF's circulate in plasma complexed to a family of binding proteins 70. To 
date six IGFBP's have been characterized 37. These IGFBP's regulate IGF availability 
between tissues and the circulation, extent the serum half life of the IGF peptides, transport 
IGF's to target cells and modulate the interaction of the IGF's with their cell surface 
receptors. In the circulation about 75 % of the IGF's are complexed with IGFBP-3. The 
remainder of circulating IGF's are bound to lower molecular weight IGFBP's, mainly 
IGFBP-1,-2 and -4. All members of the IGFBP family bind IGF-1 and IGF-2 with 
approximately equal affinity. The amount of free IGF in serum is very low and constitutes 
approximately 1-5% of the total serum IGF concentration 18.
The IGFBP synthesis is influenced by hormonal (GH, insulin, IGF's, glucocorticoids) as 
well as metabolic and nutritional factors. The IGFBP's are differentially expressed in 
various tissues depending on the stage of development and the type and age of the organ 
system.
Local modulation of the IGFBP's (and therefore of IGF activity) can be achieved through 
proteolytic modification by proteases derived from chondrocytes or at the metaphyseal 
interface from osteoblastic cells.44.
The physiological significance of limited proteolysis of IGFBP's is that protease activity 
results in decreased affinity of the IGFBP for IGF peptides, leading to increase bioavailable 
IGF peptides when needed.
IGFBP's have been found in all biological fluids. The concentrations of the various IGFBP's 
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vary among biological fluids. IGFBP-1 is the major IGFBP in human amniotic fluid 38. and 
IGFBP-2 is prominent in cerebrospinal fluid 114. IGFBP-3 is the major IGFBP in normal 
human serum and demonstrates clear GH dependence 85.
1.3.8 Thyroid hormone
Thyroxine has both an indirect and direct effect on the growth plate. An euthyroid 
state is essential for normal pituitary GH secretion.
1.3.9 Vitamin D
1,25(OH)2 vitaminD3, which could be included as an endocrine factor in the steroid 
family, regulates calcium absorption and availability. Chondrocytes can convert the 
25(OH)vitamin D to the active form for action on vitamin D receptors in the proliferative 
and hypertrophic zones of the growth plate. 1,25(OH)2D3 shows a biphasic effect on growth, 
stimulating in-vitro chondrocyte proliferation at low doses and inhibiting at higher doses 69.
1.3.10 Paracrine and other growth factors
The relative roles of GH and the IGF's in cartilage and bone development are not 
entirely clear. A current hypothesis is that GH is necessary within the growth plate for 
stimulating recruitment of the germinal/progenitor chondrocyte cells to stimulate them to 
clonal proliferation which is sustained by locally generated (GH dependent) or systemically 
derived IGF-1 22 (figure 1.4).
These endocrine stimuli, essential to normal growth, can be regarded as outside factors 
which provide the fuels and determine the pace for bone growth. However, locally 
expressed autocrine or paracrine factors govern the precise timing and coordinate cellular 
and matrix events which permit growth to proceed in an orderly manner.
Other growth factors such as transforming growth factor-b, the bone morphogenic proteins, 
platelet-derived growth factor, basic fibroblast growth factor, cytokines IL-1b, IL-6 and IL- 
8 and the IGF's interact at many levels with the functions of each of the others, cells and 
matrix constituents to enhance or inhibit processes and induce proliferation, differentiation,
25
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enzyme expression and cell death 55,117.
1.3.11 Growth in puberty
The pubertal growth spurt encompasses the most rapid phase of growth after the 
neonatal period. The pubertal growth spurt begins in girls prior to the onset of secundary 
sexual characteristics 138. Growth spurt in boys starts on the average 2 years after the 
average age of onset in girls.
The pubertal growth spurt is mediated by several endocrine influences. Sex steroids exert a 
direct effect upon the growing cartilage and stimulate local production of IGF-1 5. Increasing 
sex-steroid production stimulates increased amplitude (but not increased frequency) of 
growth hormone secretion at puberty. The increased growth hormone secretion in turn 
stimulates increased production of IGF-1. Thus pubertal growth is not only accompanied by 
higher levels of sex steroids but by increased episodic secretion of growth hormone and 
serum IGF-1 53. These direct and indirect effects of sex steroids cause the increased growth 
rate characteristic of the pubertal growth spurt. Thyroid hormone is necessary in sufficient 
amounts to allow the pubertal spurt to proceed 132.
When the pubertal growth spurt be analysed by means of individual height velocity curves, 
the phase differences between the individual curves must be taken into account.
1.4 Influence of cranial irradiation on growth
Cranial irradiation (CI) can cause damage to the hypothalamic-pituitary function 
20 106 123 148. The radiation-induced damage may result in single or multiple pituitary hormonal 
deficiencies 29. The prevalence of hormonal deficiencies is dependent on the dose and 
fractionation schedule of the irradiation administered to the hypothalamic-pituitary axis as 
well as the time elapsed since irradiation 20,29. The higher the dose of irradiation, the higher 
the incidence and the shorter the lag time between treatment and development of GH 
deficiency. The age of the patient at the time of irradiation may also be an important 
variable, with younger patients being more vulnerable than adults 128.
26
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Growth hormone deficiency (GHD) is the most frequent pituitary abnormality that occurs 
after CI 20’2930106. GHD appears to develop following CI which exposes the hypothalamic- 
pituitary region to doses in excess of 18-20 Gy 106.
Radiation-associated GH deficiency appears to result from damage to the hypothalamus, 
although at very high doses (>50Gy) the pituitary itself may also suffer direct damage 
1 106 122. Although the mechanism of radiation damage to the hypothalamus or pituitary is not 
known, it must involve a direct injury to the cells responsible for hormonal secretion, an 
injury to the stroma or its microvasculature or an injury to the vascular channels that 
transfer the hypothalamic hormones to the pituitary. The correlation between the frequency 
of TRH-dependent hypothyroidism and the interval between treatment and evaluation is 
compatible with both vascular injury and damage to parenchymal cells which have a slow 
rate of turnover 29.
In the treatment for ALL prophylactic CI, with a dose of 18-24 Gy, has been used to protect 
patients against central nervous system relapse. Growth hormone deficiency, as a sequela of 
CI, has been suggested to be the major factor for the growth retardation in these patients. 
However Brauner et al 20  showed in a prospective study that in children treated with CI no 
significant growth retardation could be attributed to GHD during the first two years after CI 
while in children with ALL growth retardation occurred immediately after start of therapy. 
Dacou-Voutetakis described in 1977 an immediate suppressive effect of irradiation upon the 
hypothalamic-pituitary function, suggesting that the poor growth velocity shown by children 
during the first year of treatment is due to radiation-induced transient GH deficiency. These 
findings could not be confirmed by other investigators. In a longitudinal study Marky et al 83 
showed no difference in GH secretion during the period of treatment, between patients who 
received no irradiation and patients who received irradiation with a dose of 18-24 Gy as 
CNS prophylaxis. So the early growth retardation in children treated for ALL cannot be 
ascribed to GH deficiency caused by CI.
Another well recognized side-effect of CI, which can influence final height, is development 
of precocious puberty. Early onset of puberty mainly occurs after high-dose CI but this side 




1.5 Influence of corticosteroids on growth
In the treatment of ALL remission-induction therapy always comprises corticosteroids. 
Several protocols also include corticosteroids during maintenance therapy. Long-term 
treatment with corticosteroids during childhood is a well recognized cause of growth 
impairment.
The mechanisms of growth suppression by corticosteroids are multifactorial with altered 
endocrine and tissue/end-organ responsiveness to many physiological regulators of the 
growth process. Corticosteroids regulate a vast array of synthesis pathways thereby 
controlling the production of various enzymes, structural proteins, receptor proteins and 
growth regulatory peptides and proteins (e.g. growth hormone, the growth hormone 
receptor, IGF-1 and most of the IGF-binding proteins). High non-physiological levels of 
corticosteroids distort the fine balance of these factors. Acute and chronic exposure to 
corticosteroids may stimulate or inhibit pituitary growth hormone release through a mixture 
of hypothalamic and pituitary effects on growth hormone releasing hormone, somatostatin 
and growth hormone synthesis 45.
The effect of excessive corticosteroids on the growth plate is shrinkage. As cell proliferation 
slows, the columns of proliferative chondrocytes become shorter and intercellular matrix 
components are disrupted by enzyme digestion 78. It is likely that similar effects are 
occurring in adjacent bone, with a shift in balance from mineral accretion toward mineral 
loss which eventually leads to osteoporosis 78. Collagen synthesis is reduced, yet degradation 
is increased as proteolytic enzymes are released to enhance degradation of the intercellular 
cartilage and bone matrix.
Some of these effects are part of a more generalized catabolic milieu resulting from the 
wider systemic impact of corticosteroids on fuel metabolism and anabolic processes 13109.
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1.6 Influence of chemotherapy on growth
Chemotherapy is the major part of the treatment for ALL and is administered both 
intravenously and intrathecally. The duration of chemotherapy in the treatment for ALL is at 
least 1.5-2.0 years. Little is known about the influence of chemotherapy on the growth 
process. Histologic examination of specimens of the distal femoral growth plates of 8 
patients treated for osteosarcoma with preoperative chemotherapy did not show complete 
growth arrest 7. In these patients the gross thickness of the plates was preserved. Columnar 
arrangement of the cells was minimally disrupted. The number of proliferative cells in each 
column was decreased and the number of hypertrophic cells was increased slightly. The 
metaphysis showed longitudinal trabeculations with a high chondroid content. Growth arrest 
lines were evidenced by transverse trabeculations with a high osteoid content, alterations 
which were ascribed to chemotherapy.
1.7 The aim of the study
The relative contributions of the disease, chemotherapy, corticosteroids or cranial 
irradiation to the growth failure noted after treatment for childhood ALL are not well 
understood.
The aim of the study
To investigate the influence on growth of the distinct entities: the disease ALL itself, 
nutritional status reflected by weight, chemotherapy, radiotherapy and corticosteroids. 
Could risk factors in the treatment for ALL be identified being responsible for growth 
retardation?
In order to answer these questions a retrospective analysis of longitudinal growth data of
29
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children treated for ALL in the University Hospital Nijmegen, is performed.
In chapter two growth during the period of treatment and 2.5 years after cessation of therapy 
is analysed. Only prepubertal patients are included in this analysis. The different influences 
of chemotherapy versus radiotherapy, high-dose chemotherapy versus low-dose 
chemotherapy and radiotherapy with a dose of 18 Gy versus radiotherapy with a dose of 24 
Gy are investigated.
In chapter three growth during maintenance therapy is analysed. Growth of patients who 
received both chemotherapy and corticosteroids during maintenance therapy is compared 
with growth of patients who only received chemotherapy during this phase of therapy. The 
patients included in this study didn't receive cranial irradiation as central nervous system 
prophylaxis.
In the chapters four and five catch-up growth is investigated. The different influences of 
cranial irradiation, chemotherapy and corticosteroids on the timing of catch-up growth is 
described in chapter four and the influences of the different treatment modalities on the 
intensity of catch-up growth is described in chapter five.
In chapter six growth during puberty of boys and girls is analysed. The patients in this study 
all received cranial irradiation as central nervous system prophylaxis. Additionally data 
about final height, age at menarche and bone age development of these patients is described.
The influence of body-weight development during and after treatment for ALL is analysed in 
chapter seven. The influence of dexamethason versus prednison, cranial irradiation and 
high-dose versus low-dose chemotherapy on weight for height is evaluated.
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1.8 Patients and Methods
1.8.1 Introduction
In our centre treatment for ALL has been given according to the consecutive protocols of 
the Dutch Childhood Leukaemia Study Group (DCLSG). Patients treated from 1972 to 1980 
received as CNS prophylaxis cranial irradiation with a dose of 24 Gy. From 1980 to 1984 
the irradiation dose for cranial irradiation was reduced to 18 Gy. In 1984 cranial irradiation 
was omitted from the DCLSG protocols. In the period 1972 to 1988 the maintenance therapy 
consisted of the combination of chemotherapy and corticosteroids. In the protocols 
commenced after 1988 the maintenance therapy did not comprise corticosteroids. The build 
up of the different protocols enabled us to investigate the influence of cranial irradiation in 
two different dose schedules, of chemotherapy and of corticosteroids on growth.
1.8.2 Treatment o f patients in this study
37 Patients treated from 1972 to 1980 received cranial irradiation with a dose of 24 Gy as 
central nervous system prophylaxis (DCLSG protocols 2 to 4).
15 Patients treated from 1980 to 1984 received cranial irradiation with a dose of 18 Gy 
(DCLSG protocol 5).
46 Patients were not irradiated but received chemotherapy as central nervous system 
prophylaxis (DCLSG protocols 6 and 7).
Of the 46 patients who didn't receive cranial irradiation, 27 patients received maintenance 
therapy comprising chemotherapy and corticosteroids (protocol 6) and of 19 patients 
maintenance therapy comprised only chemotherapy (protocol 7).
Of the 27 patients who received both chemotherapy and corticosteroids during maintenance 
therapy, the treatment of 17 patients comprised dexamethason and 10 patients received 
prednison (table 1.1).
Height and weight of each patient were measured by experienced staff. A stadiometer was 
used to measure height. During the period of treatment patients were measured 8 to 12 times
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per year and during the period of follow-up 1 to 4 times per year.
The analysis of the curves and statistical methods used are described in the various chapters. 
Table 1.1 Numbers of patients in various treatment protocols.
DCLSG Cranial irradiation No-cranial irradiation
Treatment maintenance therapy
with w i t h
without
protocol 24 Gy 18 Gy Dexa P r e d
cort














INFLUENCE OF TREATMENT MODALITIES ON 
PREPUBERTAL GROWTH IN CHILDREN WITH 
ACUTE LYMPHOBLASTIC LEUKAEMIA
J.J. Groot-Loonen, B.J. Otten, M.A. van 't Hof, R.J.J. Lippens and 
G.B.A. Stoelinga.
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Chapter 2
2.1 Abstract
Statural growth of 85 prepubertal children treated for acute lymphoblastic 
leukaemia was evaluated in a longitudinal study over 4.5 years. Patients were divided into 
three groups according to central nervous system prophylaxis: 37 received cranial 
irradiation with a dose of 24 Gy, 15 received 18 Gy and 33 were not irradiated. According 
to the risk of leukaemia, patients were divided into normal-risk (n=74) and high-risk 
patients (n=11). Duration of treatment was two years. All patients showed growth 
retardation during treatment. The relative standard deviation score for height declined from 
0 to -0.7 for the irradiated patients and to -0.2 for the non-irradiated group (p=0.0001).
No difference in growth pattern was seen between cranial irradiation with 18 versus 24 Gy 
and chemotherapeutical treatment according to high-risk versus normal-risk protocols. 
However, we demonstrated a synergistic negative effect of more intensive chemotherapy 
and cranial irradiation on growth.
2.2 Introduction
In the treatment of acute lymphoblastic leukaemia (ALL) introduction of central 
nervous system (CNS) prophylaxis and intensification of cytoreductive therapy, have led to 
an increased number of children with long-term survival 100,108. It is therefore important to 
pay attention to the late sequelae of therapy.
Cranial irradiation (CI), with a dose of 18-24 Gy, as CNS prophylaxis in the treatment of 
ALL has been associated with late sequelae, notably with neuropsychologic dysfunction and 
growth retardation 106-131-151. In an attempt to avoid these side effects CI has been omitted 
from the Dutch protocols since 1984.
Although much attention has already been paid to the statural growth of children treated for 
ALL several items are still under discussion:
36
Prepubertal growth in ALL
- Is there a difference in height of children treated with CI with a dose of 18 Gy 
compared to those irradiated with 24 Gy?
- What is the influence of chemotherapy (CT) on height of children treated for ALL? 
Results of the various studies are often difficult to compare due to differences in treatment, 
the inclusion of both prepubertal and pubertal patients, the variable methods of analysis and 
the mixture of cross sectional and longitudinal observations.
In this paper a longitudinal study on statural growth of prepubertal children treated 
for ALL is presented. To avoid pubertal influence, the follow-up of the patients in this 
study is confined to 4.5 years, as there is an indication that after treatment for ALL further 
growth retardation occurs during puberty 89. The height of children treated with CT alone 
is compared to the height of patients who received CI. The influence of two different 
radiation protocols (18 and 24 Gy) and the influence of more versus less intensive CT on 
height of children treated for ALL is investigated.
2.3 Patients and methods
Patients. Eighty-five patients (47 girls and 38 boys) with ALL treated at the Department of 
Paediatric Oncology of the University Hospital Nijmegen, between 1972 and 1988, were 
included in the study. Children with CNS involvement at the time of diagnosis were 
excluded. To avoid the influence of pubertal growth spurt, only children with age at 
diagnosis less than 10 years were included in the study. The age distribution of the patients 
is shown in figure 2.1. The data of the girls were only used for analysis up to the age of 
13.0 and boys till the age of 14.5 years. None of the patients selected according to these 
criteria showed pubertal development during the study period. All patients had entered into 
first remission within 6 weeks after diagnosis and 5 patients relapsed. They remained in the 
study till the time of relapse.
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Figure 2.1: Age distribution of girls (open bars) and boys (shaded bars) included in the study.




Patients with normal-risk leukaemia, defined as leucocyte count in the peripheral 
blood <  50.000/mm3, without mediastinal enlargement, were treated according to 
the consecutive protocols 2, 3, 5, and 6 of the Dutch Leukaemia Working Group, 
comprising induction treatment with vincristine (VCR) 2 mg/m2, prednisone (Pred) 
40 mg/m2 or dexamethason (Dex) 6 mg/m2, with or without L-asparaginase (L- 
Asp) 200 E/kg and maintenance treatment with 6-mercaptopurine (6-Mp) 50 
mg/m2 and methotrexate (MTX) 30mg/m2 alternated with VCR 2 mg/m2, Pred 40 
mg/m2 or Dex 6 mg/m2.
Patients with high-risk leukaemia, defined as leucocyte count >  50.000 mm3 
and/or mediastinal enlargement, were treated according to a more intensive high­
risk protocol comprising induction treatment with cyclophosphamide (Cyclo) 1200
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mg/m2, vincristine (VCR) 1,5 mg/m2, prednisone (Pred) 60 mg/m2, L-asparaginase 
(L-Asp) 200 E/kg, and adriamycin (Adria) 60 mg/m2. The maintenance treatment 
consisted of alternating 6-mercaptopurine (6-MP) 50 mg/m2, methotrexate (MTX) 
30 mg/m2, Cyclo 150 mg/m2 alternated with VCR 1,5 mg/m2, Pred 40 mg/m2, 
Adria 30 mg/m2 and cytosine arabinoside (Ara-C)
100mg/m2. The high-risk therapy was available since 1979.
Depending on the method of central nervous system prophylaxis, patients were 
divided into three groups:
A: received CI with a dose of 24 Gy in 13 fractions over 17 days and 5 doses MTX
12.5 mg/m2 and Pred intrathecally (i.t.) 12,5 mg/m2 (1972 - 1980).
B: received CI with a dose of 18 Gy in 10 fractions over 14 days and 5 doses MTX
12.5 mg/m2 and Pred i.t. 12,5 mg/m2 (1980 - 1984)
C: received no CI. These patients were treated with 3 courses of high dose MTX 
intravenously combined with MTX 15 mg/m2 and Pred i.t. 15 mg/m2. During 
maintenance treatment 8 doses of MTX 15 mg/m2, Pred 15 mg/m2 and Ara-C 30 
mg/m2 were given i.t. (1984 - 1988).
Table 2.1: The number of patients treated according the high-risk and normal-risk protocols and 
the three methods of central nervous system prophylaxis.
24 Gy CI 
(group A)






leukem ia 34 11 29 74
high-risk
leukem ia 3 4 4 11
total num ber 37 15 33 85
18 Gy and 24 Gy CI: the dose of cranial irradiation; non-CI: non-cranial irradiation.
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The numbers of patients treated according to the different protocols and the numbers of 
patients during the follow-up period of 4.5 years are shown in tables 2.1 and 2.2. The 
duration of treatment in all patients was two years. In this study we investigated statural 
growth during the period of treatment and the first 2.5 years after cessation of therapy.
Table 2.2: Number of patients during the 4 5 years of follow-up.
follow-up (years) 0 1 2 3 4 4.5
18 Gy CI 15 15 15 15 15 14
24 Gy CI 37 37 37 37 34 32
CI (total) 52 52 52 52 49 46
non-CI 33 33 33 25 18 14
high-risk leukemia 11 11 11 10 10 9
normal-risk leukemia 74 74 74 67 57 51
total number 85 85 85 77 67 60
18 Gy and 24 Gy CI: the dose of cranial irradiation; non-CI: non-cranial irradiation.
Measurements. Patients heights and weights were measured by experienced staff. A 
stadiometer was used to measure patients heights. During the two years of treatment 
patients were measured 8 to 12 times per year and during the years of follow-up 2 to 4 
times per year. To standardize the results and to allow comparison of children with 
different ages and sexes, values for height were transformed into standard deviation scores 
(Z-scores) using Dutch reference values 112. Z-score is defined as the difference between a 
patient's height and the age- and sex-appropriate mean of the population divided by the 
corresponding standard deviation. By means of interpolation Z-scores at six monthly 
intervals were calculated. To measure the influence of therapy the relative standard
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deviation score (Zr-score) was calculated, defined as Zr =  Zt - Z0 (Zt : Z-score at time point 
t after diagnosis, Z0: Z-score at time of diagnosis).
Statistical analysis. Statistical comparison was made using Student t-test and analysis of 
variance. Significance was accepted for p value <  0.05.
2.4 Results
At diagnosis the mean Z-score for height of all patients was -0.2 (SD 1.0) which 
was not significantly different from zero.
The Zr-scores for height of patients with and without CI are shown in figure 2.2. During 
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Figure 2.2: Mean Zr-scores ( +  SEM) for height of patients treated for ALL with (broken line) and 




After the first year of therapy the mean Zr-score was -0.2 (SD 0.3) for the non-irradiated 
and -0.5 (SD 0.5) for the irradiated patients. The difference between the two groups was 
statistically significant (p=0.004). After two years the mean Zr-score for the non-irradiated 
patients was still -0.2 (SD 0.4) and for the irradiated patients -0.7 (SD 0.6) (p=0.0001). 
After cessation of therapy an increase in Zr-score for height was shown in both groups. At 
3 and 4 years from diagnosis the mean Zr-score was 0.1 (SD 0.4) at both points for the 
non-irradiated patients and -0.4 (SD 0.7) and -0.3 (SD 0.7), respectively, for the irradiated 
patients. The differences between the two groups were still significant (p =0.002 and 
p=0.013, respectively).
The mean Zr-score for height of patients treated with irradiation dose of 18 Gy compared to 
those receiving 24 Gy did not show a significant difference.
The mean Zr-score for height of patients treated with normal-risk protocols compared to
Figure 2.3: Mean Zr-scores ( +  SEM) of height of patients treated according to normal-risk 
protocols with ( ) and without CI ( ) and high-risk protocols with ( ) and without CI 
( ). * =  p < 0 .0 5 , indicating the ANOVA significance level. A synergistic negative effect on 
statural growth of CI and high-dose chemotherapy.
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those treated according to high-risk protocols are shown in figure 2.3. Comparison of the two 
groups was made using analysis of variance with correction for irradiation. In the group of 
non-irradiated patients there was not a significant difference in Zr-scores for height 
between patients treated with CT according to a normal-risk protocol and patients treated 
with CT according to a high-risk protocol. In the group of irradiated patients, however, 
there was a decline of the Zr-score to -0.5 (SD 0.5) of the patients treated according to a 
normal-risk protocol and a decline to -1.1 (SD 0.7) of the group of patients treated 
according to a high-risk protocol. The difference between these two groups was significant 
at 1, 1.5, 2 and 2.5 years from diagnosis (p<0.05). So in the group of patients treated with 
both high-dose CT and CI there was a synergistic negative effect of these treatment 
modalities on the mean Zr-score for height.
In none of the treatment protocols the mean Zr-scores for height of boys was significantly 
different from those for girls.
2.5 Discussion
We performed a longitudinal study to the influence of different treatment 
modalities on statural growth in prepubertal children treated for ALL. The results are 
expressed in standard deviation scores which enables comparison over sexes and ages. 
Growth retardation during the remission induction and continuation periods is a well known 
observation 6668. This early deceleration in growth has been attributed to the disease itself, 
poor nutrition, the direct effect of chemotherapy, treatment with corticosteroids or CI. The 
contribution of the disease itself is minimal as height at diagnosis was not significantly 
different from the normal population 6668. In the non-irradiated patients we observed growth 
deceleration during the first six months of therapy. The next 1 1/2 years there was a normal 
growth rate, but after cessation of therapy a catch-up growth occurred. Underweight could 
have attributed to the growth deceleration during the first six months of the treatment as in 
our study the Z-score for weight for height during the first six months was below the mean 
of the normal population 51. After six months, however, the patients showed an increase in
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weight above the mean of the normal population. If underweight was the only reason for 
growth retardation the catch-up growth for height should have occurred after six months. 
Therefore these results suggest that CT and/or corticosteroids directly affect growth. Data 
of other studies 6687, are in agreement with our results. Moëll et al.87 and Katz et al. 66 
observed an initial decline in both height and growth velocity in patients who only received 
CT. Clayton et al. 27 saw a catch-up growth in the third year after diagnosis in patients who 
received 2 years CT. When CT was maintained for a further year, the catch-up growth was 
delayed by a year. These observations justify the conclusion that there is an involvement of 
CT and/or corticosteroids in early growth retardation. The effect of CT alone on final 
height is still under discussion 6792127, but CT for ALL doesn't seem to influence final 
height to a great extent. Growth retardation is clearly more marked in patients who have 
undergone radiotherapy. The physiologic basis for this growth failure is presumably 
attributable to a disturbance in the secretion of growth hormone after CI. Growth hormone 
deficiency (GHD) is the most frequent endocrine abnormality that occurs after CI 2026106. 
The occurrence of GHD depends on the estimated radiation dose delivered to the 
hypothalamus and pituitary 106 121 123. The time of occurrence of GHD is also related to the 
radiation dose 2688106. Brauner et al. 20 demonstrated in a prospective study that, although 
GHD is an early complication of CI, no significant growth retardation in patients treated 
for ALL can be attributed to GHD during the first 2 years. The early growth retardation 
shown in patients after treatment with CI for ALL might be due to an early transient 
reduction in nocturnal growth hormone secretion as reported by Dacou-Voutetakis et al. 31 
in combination with the influence of CT and/or corticosteroids.
The effects on growth of CI with a dose of 18 Gy or 24 Gy in our study were 
indistinguishable. Similar results have been described by others 131149. On the contrary, 
Cicognani et al. 25 and Logghe et al. 79 found different effects of 18 Gy and 24 Gy CI on 
growth. Cicognani et al. 25 suggested that the follow-up of the patients in the earlier 
mentioned studies 131149 of 1/2 - 1 year was too short to find such a difference. However, 
our study with a follow up of 2 1/2 years after cessation of therapy did not show any 
difference between either 18 or 24 Gy CI. The irradiation schedules were comparable in all
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studies. The explanation for the different outcome could be differences in CT. In the study 
of Logghe et al. 79 high-risk patients received CT with a total duration of 5 years, while 
normal-risk patients received CT during 2 or 3 years. Their evaluation of growth in both 
groups was 5 years after diagnosis, so a number of patients, all in the 24 Gy CI group, did 
not have the opportunity to show a catch-up growth, as they just finished their treatment. 
Additional differences were that normal-risk patients were irradiated with 18 Gy and high­
risk patients with 24 Gy and that the intensity of CT was different in both groups. Longer 
duration of chemotherapeutic treatment and more intensive CT can affect growth velocity 
140. In this longitudinal study we demonstrated that high-risk patients receiving CI showed a 
significantly greater decline in height than normal-risk patients treated with the same dose 
of irradiation. So, more intensive CT and CI have a synergistic negative effect on growth. 
This finding is supported by Shalet et al. 122, who concluded that the greater growth failure 
in the patients studied by Kirk et al 68 compared with his own patients, might be due to 
more intensive CT.
From this study it can be concluded that there is an influence of CT on short-term 
growth in patients treated for ALL. The influence of CI on statural growth is more 
pronounced, with a similar negative effect of 18 and 24 Gy. The combination of CI with 
high dose CT has a synergistic negative effect on statural growth, so in studies comparing 
the effect on growth of two different radiation protocols the difference in intensity and 
duration of CT may not be ignored. Before the general conclusion can be drawn that CT 
doesn't influence final height, further investigation is mandatory especially in patients 




CHEMOTHERAPY PLAYS A MAJOR ROLE IN THE 
INHIBITION OF CATCH-UP GROWTH DURING 
MAINTENANCE THERAPY FOR CHILDHOOD 
ACUTE LYMPHOBLASTIC LEUKEMIA





Objective: In children treated for acute lymphoblastic leukemia (ALL) catch-up growth 
occurs after cessation of therapy and not during maintenance therapy. In this study we 
investigated whether this inhibition of catch-up growth during maintenance treatment is due 
to the influence of chemotherapy or to the influence of corticosteroids.
Patients: Forty-six children treated for ALL were included in the study. In 27 patients 
maintenance therapy comprised vincristine (VCR), prednisone (Pred) or dexamethasone 
(Dexa) alternated with 6-mercaptopurine (6-MP) and methotrexate (MTX) and 19 patients 
received maintenance therapy with 6-MP and MTX only. Treatment did not include cranial 
irradiation.
Results: Statural growth during maintenance treatment was comparable in both groups over 
the study period of 1.5 years.
Conclusion: Chemotherapy with 6-MP and MTX and not corticosteroids is the main factor 
that prevents catch-up growth to occur during maintenance therapy for ALL.
3.2 Introduction
Growth retardation during treatment for acute lymphoblastic leukemia (ALL) has 
been demonstrated in many studies 16>27"49"59>68"77"87 135. Diminished growth during treatment 
could be caused by several factors including the disease itself, infections and poor nutrition, 
but cranial irradiation (CI), chemotherapy and corticosteroids have been proposed as the 
main etiologic agents 27>49>59"68"77 135. The greatest part of the growth retardation occurred 
during the remission induction therapy, a phase of intensive chemotherapy. Catch-up 
growth did not occur before cessation of therapy 16-27-49-59-77-87. Maintenance therapy seemed 
not to affect growth to a great extent, however, maintenance therapy did prevent a catch-up 
growth to occur. Several authors assumed that this inhibition of catch-up growth is mainly 
due to the effect of steroids 5977135. In this study we investigated the influence of
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corticosteroids on growth during maintenance therapy. We evaluated growth of children 
with ALL treated according to two different protocols: in the first protocol corticosteroids 
were a part of the maintenance therapy, in the second protocol maintenance therapy only 
comprised chemotherapy.
3.3 Patients and methods
Patients. Forty-six patients (19 girls and 27 boys) with ALL treated at the Department of 
Paediatric Oncology of the University Hospital Nijmegen, between 1984 and 1991, were 
included in the study. Patients with high-risk ALL, defined as leucocyte counts >  
50.000/mm3 and/or mediastinal enlargement and patients with central nervous system 
involvement at time of diagnosis were excluded. To avoid the influence of pubertal growth 
spurt only children with age less than 10 years at diagnosis were included in the study. Age 
distribution was 1.6 - 9.9 year, median age 5.1 years.
Treatment. Twenty-seven patients were treated with chemotherapy according to protocol 6 
of the Dutch Leukemia Working Group.
Protocol 6 comprised: 
a: Induction treatment with Vincristine (VCR), Dexamethasone (Dexa) or 
Prednisone (Pred) with L-Asparaginase (L-Asp) and two doses of 
Methotrexate (MTX) and prednisone intrathecally. 
b: Central nervous system prophylaxis with high-dose MTX intravenously, and 
three doses MTX plus Prednisolone intrathecally. 
c: Maintenance treatment with 2 weeks of VCR plus Pred or Dexa alternated 
with 5 weeks 6-Mercaptopurine (6-MP), 50 mg/m2 daily, plus MTX 30 
mg/m2 once a week and 8 courses of MTX, Prednisolone and Cytosine- 
Arabinoside (ARA-C) intrathecally 
Seventeen out of the 27 patients treated according to protocol 6 received Dexa, 6 mg/m2, 
during induction and maintenance treatment and in 10 patients Dexa was replaced by Pred
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40 mg/m2. The duration of induction treatment and central nervous system prophylaxis was 
3 months, so maintenance therapy started 3 months after diagnosis. Total duration of 
treatment was 2 years.
Nineteen patients were treated according to protocol 7 of the Dutch Leukemia 
Working Group.
Protocol 7 comprised: 
a: Induction treatm ent w ith VCR, Pred, D aunorubicin , L -A sp, 
Cyclophosphamide, ARA-C and 6-MP and three doses MTX intrathecally. 
b: Central nervous system prophylaxis with high-dose Methotrexate (MTX) 
intravenously, 6-MP orally and four doses of MTX intrathecally. 
c: Re-induction treatment w ith VCR, D exa, Adriam ycin, L-Asp, 
Cyclophosphamide, ARA-C and 6 Thioguanine and two doses of MTX 
intrathecally.
d: Maintenance treatment with 6-MP, 50 mg/m2 daily, and MTX, 20 mg/m2 
once a week. The maintenance treatment started 7 months after diagnosis.
Total duration of treatment was 1.5 years. None of the patients in this study 
received cranial irradiation.
In this study we investigated statural growth during 1.5 years of therapy.
Measurements and statistical analysis. Patients height and weight was measured by 
experienced staff. During the study period patients were measured 12 times per year. To 
standardize the results and to allow comparison of children with different ages and sexes, 
values for height were transformed into standard deviation scores using the Dutch reference 
values 112. Standard deviation score for height is defined as the difference between a 
patients height and the age- and sex-appropriate mean of the population divided by the 
corresponding standard deviation. Estimates of the standard deviation scores at regular time 
intervals (3 months) were obtained by interpolation of the individual standard deviation 
score curves. To measure the influence of therapy properly the relative standard deviation
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score (Zr-score) was calculated, defined as: Zr =  Zt - Z0 (Zt: standard deviation score at 
time point t after diagnosis, Z0: standard deviation score at time of diagnosis).
Statistical comparison was made using the t-test on the Zr-scores. Zr-scores are presented 
with +  the standard deviation.
3.4 Results
The Zr-scores for height of the 27 patients treated for ALL according to protocol 6 
(maintenance therapy comprising Pred or Dexa) compared with the Zr-scores of 19 patients 
treated according to protocol 7 (maintenance treatment without corticosteroids) are shown 
in figure 3.1. Height at diagnosis was not significantly different from the normal 
population. During treatment a decline in Zr-score for height was shown in both groups. 
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Figure 3.1: Mean Zr-score ( +  standard error) for height of patients treated for ALL according to 
protocol 6 (maintenance therapy comprising Prednisone or Dexamethasone, n=27) (solid line) and 
according to protocol 7 (maintenance treatment without corticosteroids, n=19) (broken line).
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protocol 6 was -0.2 +  0.2. The Zr-score remained -0.2. The Zr-score of patients treated 
according to protocol 7 was -0.3 +  0.2 at 3 months and remained -0.3 during the whole 
period of treatment. The differences between the two groups were not significant at any 
time (all p-values 0.10).
3.5 Discussion
Growth retardation during treatment for ALL is of multifactorial etiology 27. CI as 
central nervous system prophylaxis in the treatment for ALL has been implicated as main 
etiologic agent 49. Compared to patients who were not irradiated, children who received CI 
showed more severe growth retardation and during the period of catch-up growth these 
patients did not fully regain the previous loss 27-49-59-77-87. Children treated for ALL with 
chemotherapy and corticosteroids but without CI also showed diminished growth rate 
during treatment 49’5987. Apart from impaired growth, retardation of bone-age development 
has also been reported during treatment for ALL 134. Bone age retardation in patients who 
received CI was the same as in patients who were not irradiated, suggesting a direct 
influence of chemotherapy and/or corticosteroids on skeletal maturation 134. The influence 
of chemotherapy alone on growth and bone-age development is not known, but long-term 
corticosteroid therapy has been associated with growth inhibition and delayed skeletal 
maturation 61,93. Short-term treatment with prednisone in a dose of 40 mg/m2/day and 
dexamethasone in a dose of 10 mg/m2/day, used during remission induction therapy for 
ALL have been shown to suppress growth hormone secretion 1983. This temporary 
inhibition of growth hormone secretion could contribute to the diminished growth during 
the early phase of therapy. In this study both groups of patients showed loss of height 
standard deviation score during the initial phase of therapy. The question was whether 
patients who did not receive corticosteroids during maintenance treatment would show a 
different growth pattern compared to children who received corticosteroids during the 
entire period of treatment. Although in protocol 6 corticosteroids were given intermittently
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(2 weeks on steroid treatment, 5 weeks off) this mode of treatment has also been associated 
with impaired growth 93. However, the growth pattern in both groups of patients during 
maintenance therapy proved to be the same, none of the patients showed catch-up growth. 
So we may conclude that corticosteroids were not the causal factor for inhibition of catch­
up growth but that this phenomena was mainly due to chemotherapy with 6-MP and MTX. 
Treatment with MTX has been associated with enteropathy 75 which could result in 
malnutrition. For patients treated according to protocol 7 (without corticosteroids during 
maintenance therapy) weight for height was not significant different from the normal 
population, from this we conclude that malnutrition could not be a factor contributing to the 




CATCH-UP GROWTH IN ACUTE LYMPHOBLASTIC 
LEUKAEMIA; INFLUENCE OF TREATMENT 
MODALITIES ON TIMING.





Catch-up growth was investigated in 76 children treated for acute lymphoblastic 
leukaemia; 41 patients received cranial irradiation (protocols 2,3,5), maintenance therapy 
comprised chemotherapy and corticosteroids in 61 (protocols 2,3,5 and 6) and 
chemotherapy only in 15 patients (protocol 7). Individual, longitudinal curves for growth- 
velocity and acceleration were constructed. The Z-velocity was distracted from the Z-score 
for height. Timing of ONSET, START and PEAK of catch-up growth and timing of 
accelerated growth were analysed for three groups of patients: 1. Patients who received 
cranial irradiation as central nervous system prophylaxis and corticosteroids during 
maintenance therapy (protocols 2,3 and 5), 2. patients treated without cranial irradiation but 
with corticosteroids during maintenance therapy (protocol 6) and 3. patients treated without 
cranial irradiation and without corticosteroids during maintenance therapy (protocol 7).
The Z-velocity increased during treatment. The start of the positive Z-velocity, which is the 
start of catch-up growth, was respectively 2.0, 1.3 and 1.0 years after diagnosis for the 
protocols 2-5, 6 and 7. The time-interval from onset to peak of catch-up growth was 
comparable for all patients. Growth was accelerated immediatly after start of therapy. The 
acceleration decreased during treatment. The end of the accelerated growth was 2.5, 2.2 
and 1.9 years after diagnosis for respectively protocol 2-5, 6 and 7. So it can be concluded 
that acute lymphoblastic leukaemia itself has an influence on growth. The start of the catch­
up growth is independent of cessation of therapy. The duration of catch-up growth is not 
influenced by different treatment modalities.
4.2 Introduction
The growth potential of a person is genetically determined and under favorable 
conditions each individual will follow a predominated growth curve 4. Growth retardation, 
a deflection away from the predicted growth curve, can be caused by various diseases,
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malnutrition, psychosocial stress or endocrine disorders 447141.
When a period of growth retardation ends and favorable conditions are restored, a period of 
accelerated growth will occur 4152. This acceleration in growth is referred to as "catch-up 
growth". It is a self correcting response which restores individuals to their original growth 
channel. The extent to which growth failure can be compensated for depends on timing, 
severity and duration of the growth failure, as well as on the aetiology and pathogenesis of 
the disease restricting growth 71.
Growth retardation during treatment for acute lymphoblastic leukaemia (ALL) has been 
demonstrated in a number of studies 16-27-49-59-87. Treatment for ALL comprised 1. induction 
therapy with chemotherapy (CT) and corticosteroids, 2. central nervous system (CNS) 
prophylaxis with radiotherapy or CT and 3. maintenance therapy with CT with or without 
corticosteroids. The treatment modalities CT, corticosteroids and cranial irradiation (CI) 
have been proposed as the main etiologic factors for growth retardation in these patients 
49,59. After cessation of therapy catch-up growth was demonstrated in all patient groups 
16,27,49,59,87. In patients treated without CI growth returned completely to the predicted 
growth curve whereas in patients who received CI as a part of their treatment the catch-up 
growth was incomplete 27’4987. This study was performed to investigate the effects of the 
different treatment modalities: chemotherapy, irradiation and corticosteroids, on catch-up 
growth of children treated for ALL. To gain more insight into the growth patterns of these 
patients, not only heights achieved at different time points were analysed, but we also 
analysed velocities as velocity detects alterations in growth regardless of the stature 
achieved.
4.3 Patients and methods
Patients. Seventy-six consecutive patients (39 girls and 37 boys) with ALL treated at the 
Department of Pediatric Oncology of the University Hospital Nijmegen between 1972 and 
1991 were included in the study. To avoid the influence of the pubertal growth spurt only
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patients with age at diagnosis of less than 7 years were included. The patients had entered 
into first remission within 6 weeks after diagnosis. The follow-up of the patients was at 
least two years after cessation of therapy. Patients who relapsed were excluded. As CNS 
involvement can cause hypothalamic dysfunction 8, patients with CNS involvement at the 
time of diagnosis were also excluded.
Treatment. According to the year of diagnosis of ALL, patients were treated according to 
the protocols 2, 3, 5, 6 and 7 of the Dutch Leukemia Working Group. Patients were 
divided into three groups: 1. patients treated according to the protocols 2, 3 and 5. These 
patients received both cranial irradiation as CNS prophylaxis and corticosteroids and 
chemotherapy during maintenance therapy (n=41). 2. Patients treated according to protocol 
6. These patients did not receive CI as CNS prophylaxis, the maintenance therapy 
comprised both chemotherapy and corticosteroids (n=20). 3. Patients treated according to 
protocol 7 received neither CI as CNS prophylaxis nor corticosteroids during maintenance 
therapy (n=15).
Protocol 2,3,5: these protocols were used for patients diagnosed in between 1972-1984.
The protocols 2,3 and 5 comprised: Induction treatment with Vincristine (VCR) 2 mg/m2, 
Prednisone (Pred) 40 mg/m2 with or without L-Asparaginase 200 E/kg.
Maintenance treatment with 5 weeks of 6-Mercaptopurine (6-MP) 50 mg/m2 daily and 
Methotrexate (MTX) 30 mg/m2 once a week, alternated with 2 weeks of VCR 2 mg/m2 and 
Pred 40 mg/m2. Patients of protocol 2 also received Cyclophosphamide 200 mg/m2 every 2 
weeks.
CNS prophylaxis: CI with a dose of 24 Gy in 13 fractions over 17 days and 5 doses MTX
12.5 mg/m2 and Pred 12.5 mg/m2 intrathecally (i.t.) (protocols 2 and 3) (1972-1980). CI 
with a dose of 18 Gy in 10 fractions over 14 days and 5 doses MTX 12.5 mg/m2 and Pred
12.5 mg/m2 i.t. (1980-1984) (protocol 5).
The aimed duration of treatment was 2 years.
Protocol 6: This protocol was used for patients diagnosed in between 1984-1988.
Protocol 6 comprised: Induction treatment with VCR 2 mg/m2, Dexamethasone 6 mg/m2 or 
Pred 40 mg/m2 and L-Asparaginase 200 Units/kg.
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Maintenance treatment with 5 weeks of 6-MP 50 mg/m2 daily and MTX 30 mg/m2 once a 
week, alternated with 2 weeks of VCR 2 mg/m2 and Dexamethason 6 mg/m2 or Pred 40 
mg/m2.
CNS prophylaxis with 3 courses of intermediate-dose MTX 2000 mg/m2 intravenously 
(i.v.) combined with MTX 15 mg/m2 and Pred 15 mg/m2 intrathecaly. During maintenance 
treatment 8 doses of MTX 15 mg/m2, Pred 15 mg/m2 and Cytarabine 30 mg/m2 were given
i.t..
The aimed duration of treatment was 2.25 years.
Protocol 7: This protocol was used for patients diagnosed in between 1988-1991.
Protocol 7 comprised: Induction treatment with VCR 1.5 mg/m2, Pred 60 mg/m2, 
Daunorubicin 40 mg/m2, L-Asparaginase 10000 E/m2, Cyclophosphamide 1000 mg/m2, 
Cytarabine 75 mg/m2 and 6-MP 60 mg/m2.
Consolidation treatment with VCR 1.5 mg/m2, Dexamethason 10 mg/m2, Adriamycine 30 
mg/m2, L-Asparaginase 10000 E/m2, Cyclophosphamide 1000 mg/m2, Cytarabine 75 
mg/m2 and 6-Thioguanine 60 mg/m2.
Maintenance treatment with 6-MP 50 mg/m2 daily and MTX 20 mg/m2 once a week.
CNS profylaxis with 4 courses of high-dose MTX 5000 mg/m2 i.v. combined with MTX 15 
mg/m2 i.t. and 6-MP 25 mg/m2 orally.
The aimed duration of treatment was 1.5 years.
Summary of treatment: 41 patients received cranial irradiation (protocols 2,3 and 5), 61 
patients received chemotherapy and corticosteroids during maintenance therapy (protocols 6 
and 7) and 15 patients received only chemotherapy during maintenance therapy (protocol 
7).
Measurements. Patients heights were measured by experienced staff using a stadiometer. 
During the years of treatment patients were measured 12 times per year and during the 
years of follow-up 4 times per year.
To standardize the results and to allow comparison of children with different ages and 
sexes, values for height were transformed into standard deviation scores (SDS or Z-scores) 
using Dutch reference values 112. Z-score is defined as the difference between a patient's
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height and the age- and sex-appropriate mean of the population divided by the 
corresponding standard deviation.
Velocity and acceleration curves. During a period of catch-up growth, a child is regaining 
length with respect to its peer group. This implies an increasing Z-score and a period in 
which the Z-velocity is positive. In order to detect such periods of catch-up growth it is 
necessary to study changes in Z-velocity, given by the Z-acceleration curve.
At the same time also the growth velocity in height itself is changing. To obtain a complete 
impression of catch-up growth, individual height- and Z-velocity curves are studied 
together with height- and Z-acceleration curves. For this purpose the statistical technic of 
the Kernel estimation 41,42 was used. The Kernel estimation is a smoothing procedure using 
polynomials up to the degree of 7, holding for a prechosen band width. In this study two 
different sets of band widths for time, as introduced by Gasser 42, were
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Figure 4.1: Mean Z-score (SDS for height +  SEM) of patients treated according to protocol 2-5 
( ) n=41, protocol 6 ( ) n=20 and protocol 7 ( ) n=15.
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used: 1. a band of 3.1 years for velocity and 3.6 years for acceleration and 2. a band of 3.8 
years for velocity and 4.0 years for acceleration. The Kernel estimation was applied on 
individual, longitudinal measurements. Individual, longitudinal curves for growth velocity 
and acceleration, from diagnosis to two years after cessation of therapy, were obtained.
Statistics. Comparison of time points derived from the individual velocity and acceleration 
curves with respect to the 3 treatment protocols were made using one way analysis of 
variance (ANOVA). Significance was accepted for p values less than 0.05.
4.4 Results
Time curves for Z-scores. The mean Z-scores for height are shown in figure 4.1. At 
diagnosis there is no significant difference in Z-score between the three treatment groups 
(ANOVA, p=0.60). This means that the 3 groups were initially comparable.
During the years of therapy a significant growth retardation was found in the patients 
treated with CI (protocols 2,3 and 5), (paired t-test, p <0.001) with a mean Z-score =  -
0.8 (SEM =0.15). The Z-score of this group increased up to -0.5 (SEM =  0.13) after 
cessation of therapy, indicating an incomplete catch-up growth.
For the protocols 6 and 7, without CI, also a decrease in mean Z-score was found followed 
by a complete catch-up growth.
Timing of catch-up growth. Figure 4.2 shows the Z-velocity curve and the Z-acceleration 
curve for a representative patient. Initially the Z-velocity is negative, indicating a period of 
growth retardation. This period was followed by a period with a positive Z-velocity, where 
the patient is regaining height compared to the peer group, i.e. the period of catch-up. The 
end of the catch-up growth is beyond the follow-up of two years after cessation of therapy 
for most of the patients.
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Figure 4.2: Curve of the Z-acceleration (SD/year2) ( ) and the Z-velocity (SD/year) ( ) of a 
representative patient. The timing of the ONSET, the START and the PEAK of catch-up growth 
are indicated. The vertical (dotted) line indicates the moment of cessation of therapy.
The timing of the catch-up growth is marked by 3 time points i.e.
- The moment were the negative Z-velocity is increasing, marked by a zero Z- 
acceleration. This time point may be regarded as the ONSET of catch-up growth.
- The moment that the Z-velocity reaches a positive value. This may be regarded as 
the START of catch-up growth.
- The moment that the Z-velocity reaches its PEAK value, marked by the second 
time that the Z-acceleration becomes zero.
Such a pattern of catch-up growth was found in 66 out of the 76 patients. For 18 out of the 
76 patients the Z-acceleration was already, slightly, positive at diagnosis and the moment of 
onset of catch-up growth could easily be obtained by backward extrapolation of the Z- 
acceleration curve, leading to a negative value (before start of therapy) for the onset.
In 6 out of the 76 patients (2 patients of protocol 5, 3 patients of protocol 6 and 1 patient of 
protocol 7) the Z-velocity was almost zero during the whole period of the study. These
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patients were "tracking" and no growth retardation or catch-up growth could be observed.
In 4 out of the 76 patients (2 patients of protocol 5 and 2 patients of protocol 7) the Z- 
velocity was negative during the whole study period. These patients suffered from growth 
retardation without any sign of catch-up growth.
Thus for 66 patients the start of catch-up growth could be identified. On the basis of the Z- 
acceleration curves it was possible to identify both the minimal (onset of catch-up) and 
maximal Z-velocity (peak of catch-up) for all 76 patients.
Table 4.1: Mean +  SD (n) of the three moments in catch-up growth for the three groups of 
patients treated according to the protocols 2-5, 6 and 7 and the corresponding time of cessation of 
therapy given in years after diagnosis.
Moment protocol 2-5 (n) protocol 6 (n) protocol 7 (n)
Onset 0 .41+0.48 (41) 0 .05+0.46 (20) -0.08+0.59 (15)
Start 2.02+0.55 (36) 1.31+0.34 (16) 1.04+0.69 (14)
Peak 2.99+0.72 (41) 2.45+0.55 (20) 2.51+0.83 (15)
Cessation of  
therapy 2.0 2.25 1.5
For all three moments protocols 2-5 are significantly later than protocol 6 and 7 (ANOVA, all p-values <  
0.01).
A comparison of the three protocols with respect to the three time points is given in table
4.1. Table 4.1 shows that all three catch-up moments are significant later in the protocols
2,3 and 5 (with CI) compared to the protocols 6 and 7 (without CI).
On the average the start of catch-up growth in the protocols 2-5 coincides with cessation of 
therapy, but in protocol 6 and 7 catch-up growth starts in general before cessation of 




Table 4.2: Mean +  SD (n) for the time intervals between the three moments in catch-up growth 
for the three groups of patients treated according to the protocols 2-5, 6 and 7.
Interval protocol 2-5 (n) protocol 6 (n) protocol 7 (n)
Onset - Start 1.50+0.32 (36) 1.12+0.17 (16) 1.24+0.35 (14)
Start - Peak 1.13+0.42 (36) 1.31+0.25 (16) 1.36+0.54 (14)
Onset - Peak 2.58+0.53 (41) 2.41+0.17 (20) 2.47+0.72 (15)
The duration of the interval onset - start is significant different for the three groups (ANOVA, p < 0 .01).
The only significant difference between the protocols is the duration of the interval onset - 
start (ANOVA, p< 0 .01), indicating a larger interval for the protocols 2-5.
The growth velocity on its own is not informative for the timing of catch-up growth since 
growth velocity is positive also in children treated for ALL. From the acceleration curves 
obtained by the Kernel estimation, the start of the acceleration of growth could not be 
indicated in this group of children. Such a point did not appear as, surprisingly, growth was 
accelerated immediately after start of therapy (figure 4.3). Instead of an acceleration curve 
changing from negative into positive, which was expected, the acceleration curve changed 
from positive into negative in all children. The end of the positive acceleration (point a, 
figure 4.3) was calculated for the different groups of patients.
The mean end of the period of the accelerated growth was 2.52 years (SD 0.72) after 
diagnosis for children treated according to the protocols 2-5 and 2.18 (SD 0.50) and 1.93 
(SD 0.32) years after diagnosis for patients treated according to protocols 6 and 7 
respectively. The difference in duration of accelerated growth between the protocols was 
significant (p=0.004, ANOVA).
In applying the Kernel estimation two different band widths (smoothing parameters) were 
used. Compared to the results of the 3.1-3.6 band the end of the accelerated growth was
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significant later: 0.07 (SD 0.16) year, the timing of the minimal Z-velocity was 
significantly earlier: 0.06 (SD 0.06) year, the timing of the maximal Z-velocity was 0.04 
(SD 0.13) year later and the start of the positive Z-velocity was 0.06 (SD 0.21) year later 
than in the 3.8-4.0 band. Despite the significant influence of the bandwidth, it may be 
concluded that the sensivity to band width choice is only small.
4.5 Discussion
Z-score for height declined during the period of treatment in the three groups of 
patients. The decrease was most pronounced in the patients who received cranial irradiation 
as CNS prophylaxis (protocols 2-5) and in this group the catch-up growth was incomplete, 
which is in agreement with other studies 27’4987. The treatment modalities have been thought 
to be the main causal factors for growth retardation as catch-up growth did
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Figure 4.3: Curve of acceleration of growth (cm/year2) of the same patient as figure 4.2. The end 




not occur during the period of treatment 50. However, despite growth suppressive therapy, 
in all patients, acceleration of growth was demonstrated as soon as therapy was instituted. 
This could imply that the leukemic process is an important causal factor for growth 
suppression.
The majority of the patients, diagnosed for ALL, present with skeletal lesions. These 
lesions, observed roentgenographically, are juxtaepiphyseal radiolucent bands, osteoporosis 
and osteolytic lesions 139. The pathogenesis of the skeletal lesions in ALL could be 
understood from the role of the hematopoietic bone-marrow in bone-cell development. Both 
osteoblasts and osteoclasts originate in the marrow. Cells of the bone and the hematopoietic 
bone marrow share progenitors and produce and respond to some of the same cytokines and 
colony-stimulating factors 82. Disease of the bone marrow will cause disruption of the bone­
cell development with growth arrest or disturbed growth in children. In most patients 
complete remission of ALL will be achieved within six weeks after start of therapy, with 
recovery of the hematopoiesis and restoration of bone-cell development. So soon after 
institution of therapy acceleration of growth could occur and our results are in concurrence 
with this phenomenon.
Despite accelerated growth in this period, the Z-score for height declined during the early 
phase of therapy.
The decrease in Z-score for height was the most severe in patients who received CI as CNS 
prophylaxis 27,59 and especially in these patients the period of acceleration of growth was 
significantly longer than in the other patients. The more severe growth retardation, during 
the first months of treatment, of the patients who received CI is not well understood. The 
physiologic basis for growth failure after CI is thought to be a disturbance in the secretion 
of growth hormone 29. However Brauner et al 20 demonstrated in a prospective study that 
although growth hormone deficiency is an early complication of CI, in patients treated for 
ALL no significant growth retardation can be attributed to growth hormone deficiency 
during the first 2 years after CI. In this study we demonstrated an acceleration of growth, 
in all patients, already in the early phase of therapy. During a period of accelerated growth 
children are more susceptible to the detrimental effects of growth suppressive therapy and 




For patients who received CI as a part of their treatment the Z-velocity decreased during 
the first 5 months of therapy (the onset of catch-up was 5 months after diagnosis, table
4.1). For patients treated according to protocol 6, a decrease of Z-velocity was 
demonstrated during the first month of therapy. In this phase the greatest loss in Z-score 
for height occurred. The patients of protocol 7 showed an increase of Z-velocity 
immediately after start of therapy.
Despite an increase in Z-velocity, during the early phase of therapy, the Z-score for height 
did not increase before the Z-velocity became positive. So the start of the positive Z- 
velocity is the beginning of the catch-up growth. The start of the positive Z-velocity was 2 
years after diagnosis for patients of the protocols 2-5 and 1.3 and 1.0 years after diagnosis 
for patients of protocols 6 and 7. For patients treated according to the protocols 2-5 the 
start of the catch-up growth coincides accidently with the cessation of therapy. These 
results could, erroneously, support the conclusion that the start of the catch-up growth was 
related to the cessation of therapy.
The start of the positive Z-velocity was earliest after diagnosis in patients of protocol 7, the 
patients who, apart from no CI as CNS prophylaxis, did not receive corticosteroids during 
maintenance therapy. This might lead to the conclusion that growth suppression is 
prolonged in patients treated with corticosteroids as a part of maintenance therapy. 
However this is not in concordance with results of a previous study to the influence of 
maintenance therapy on growth in children treated for ALL 50. In this study we showed that 
during maintenance therapy the relative Z-score for height of patients treated with CT and 
corticosteroids was comparable to the relative Z-score for height of patients who received 
only CT.
As far as the duration of catch-up growth is concerned, the time interval between the onset 
of catch-up growth and the peak value is important as during this phase the Z-velocity 
increased. No difference between the protocols was noticed for this time interval. Neither 
there was a difference in time interval in between the start of catch-up growth and the 
timing of the peak value, which is not only a period of increase in Z-velocity but also a 
period of positive Z-velocity. So although the catch-up growth is incomplete in the
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irradiated patients, in contrast to the non-irradiated patients who fully regain the previous 
loss, the duration of the catch-up growth is comparable for all patients.
A limitation in the application of the Kernel estimation could be the choice of the 
smoothing parameter (band width). Gasser 42 suggested a smoothing parameter of 3.1 year 
for velocity during puberty, a period of increased growth velocity, and 3.8 year for velocity 
before puberty. We applied both smoothing parameters. The difference between the two 
parameters was a small shift of less than one month of the end of the accelerated growth 
and the timing of the onset, the start and the peak value of catch-up growth 
From this study it can be concluded that:
- Acute lymphoblastic leukaemia, as such, has a negative influence on growth 
velocity. Growth accelerates as soon as therapy is instituted.
- The causal factor for the decrease in Z-score for height, despite accelerated growth 
and increase in Z-velocity during treatment, is the suppressive effect on growth of 
the treatment modalities instituted.
- The strongest growth suppressive effect is cranial irradiation.
- The start of the catch-up growth, which is the start of the positive Z-velocity, is 
independent of the moment of cessation of therapy.
- The duration of catch-up growth is comparable for all patients, regardless the 
treatment protocol.
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INTENSITY OF CATCH-UP GROWTH DURING AND  
AFTER TREATMENT FOR ACUTE LYMPHOBLASTIC 
LEUKAEMIA.





Catch-up growth was investigated in 76 children treated for acute lymphoblastic 
leukaemia; 41 patients received cranial irradiation and 35 patients were not irradiated. 
Curves for Z-acceleration and Z-velocity were distracted from the Z-scores for height. To 
describe the intensity of catch-up growth: the minimal Z-velocity, the maximal Z-velocity 
and the difference between minimal and maximal Z-velocity were analyzed for patients with 
and without irradiation. The magnitude of the minimal Z-velocity of the irradiated patients 
was significantly lower. The magnitude of the maximal Z-velocity was comparable in both 
groups. The difference between the minimal and the maximal Z-velocity, which is a degree 
for the intensity, was significantly higher in the irradiated patients. The SDS for height at 
maximal Z-velocity was significantly lower in the irradiated patients. So despite a more 
intensive catch-up growth, the irradiated patients have a significantly greater loss in height 
SDS, which supports the hypothesis of a reset of the mechanism which recognizes normal 
body size, to a smaller body size by cranial irradiation.
5.2 Introduction
Normal human growth is characterized by growth according to a predicted growth channel. 
This growth channel is genetic determined and observed from the peer group 136. A 
negative deflection away from this predicted growth channel can be caused by various 
conditions such as chronic diseases, malnutrition or endocrine disorders 4103. Catch-up 
growth towards the original growth curve, will occur after a period of growth retardation, 
provided that the favourable conditions are restored.
A disease which is attended with growth retardation is acute lymphoblastic leukaemia 
(ALL) 2759140. The causal factors for growth retardation in ALL could be the disease itself 
or treatment with chemotherapy, radiotherapy and corticosteroids.
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In a previous study to the timing of catch-up growth in ALL 48 it was shown that growth 
velocity was already low at diagnosis. From this we concluded that the disease ALL has an 
influence on growth. After institution of treatment with chemotherapy, corticosteroids and 
with or without radiotherapy, acceleration of growth was noticed. So despite the growth 
suppressive effects of the treatment modalities, growth accelerated as soon as therapy 
commenced. However during the early period of treatment the attained growth velocity was 
below the growth velocity of the normal population leading to a decrease in standard 
deviation score for height. After a period of time the patients growth velocity was above the 
growth velocity of the normal population and catch-up growth appeared. In patients who 
received prophylactic, cranial irradiation to protect against central nervous system (CNS) 
relapse, the catch-up growth was incomplete whereas in patients who only received 
intrathecal chemotherapy to prevent CNS leukemia, height returned to the initial predicted 
growth curve. The duration of catch-up growth was comparable for both irradiated and 
non-irradiated patients 48.
In this study we investigated the intensity of catch-up growth in patients treated for ALL, in 
relation to different treatment modalities.
5.3 Patients and methods
Patients. Seventy-six consecutive patients (39 girls and 37 boys) with ALL treated at the 
Department of Pediatric Oncology of the University Hospital Nijmegen between 1972 and 
1991 were included in the study. Inclusion criteria:
- Age at diagnosis <  7 years, to avoid the influence of the pubertal growth spurt.
- Achievement of complete remission within six weeks after start of therapy.
- Follow-up of at least 2 years after cessation of therapy.
- No relapse of ALL during treatment and within two years after cessation of 
therapy.
- No CNS involvement as CNS involvement can cause hypothalamic dysfunction 8.
73
Chapter 5
Treatment. According to the year of diagnosis of ALL, patients were treated according to 
three consecutive protocols 2 up to 7 of the Dutch Leukemia Working Group.
Protocols 2,3 and 5 were used for patients diagnosed in between 1972 and 1984 (n=41). 
These protocols comprised cranial irradiation (CI) with a dose of 18 or 24 Gy as CNS 
prophylaxis and patients received corticosteroids and chemotherapy during maintenance 
therapy.
CI commenced 6 weeks after start of therapy.
Protocol 6 was used for patients diagnosed in between 1984 and 1988 (n=20). This was a 
protocol without CI as CNS prophylaxis with chemotherapy and corticosteroids during 
maintenance therapy.
Protocol 7 was used for patients diagnosed in between 1988 and 1991 (n=15). This 
protocol did neither comprise CI as CNS prophylaxis nor corticosteroids during 
maintenance therapy. Detailed information about chemotherapy is described in a previous 
paper 48.
Measurements. Patients heights were measured by experienced staff. A stadiometer was 
used to measure patients heights. During the period of treatment, patients were measured 
12 times per year and during the follow-up period, 4 times per year.
To standardize the results and to allow comparison of children with different ages and 
sexes, values for height were transformed into standard deviation scores (Z-scores or SDS- 
scores) using Dutch reference values 112. The Z-score is defined as the difference between a 
patients height and the age and sex appropriate mean of the population relative to the 
corresponding standard deviation.
Catch-up growth is most clearly defined as regaining height (relative to the peer group) and 
can be quantified as positive changes in Z-score over time. Therefore Z-velocities and Z- 
accelerations play an important role in the study of catch-up growth.
Velocity and acceleration curves. For the calculation of velocities and accelerations the 
Kernel estimation 4142 was used. The Kernel estimation is a smoothing procedure using 
polynomials up to a degree of 7, holding for a pre-chosen band width for time.
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Figure 5.1: Curve of the Z-acceleration (SDS/yr2)( ) and the Z-velocity (SDS/yr)( ) of a 
representative patient. The minimal Z-velocity (MiVZ), the maximal Z-velocity (MaVZ) and the 
difference between the MiVZ and the MaVZ ( VZ) are indicated. The vertical dotted line ( ) 
indicates the moment of cessation of therapy.
In this study two different sets of band widths, as introduced by Gasser 42, were used: band
1 of 3.1 years for velocity and 3.6 years for acceleration and band 2 of 3.8 years for 
velocity and 4.0 years for acceleration.
As catch-up growth is defined as growth velocity above the growth velocity of the normal 
population, Z-velocity and Z-acceleration were distracted from the Z-scores for height. 
Using the Kernel estimation time curves for Z-velocity and Z-acceleration, from diagnosis 
to two years after cessation of therapy, were obtained.
To describe the intensity of catch-up growth two events were analysed ie minimal Z- 
velocity (MiVZ) and maximal Z-velocity (MaVZ) (see figure 5.1).
Estimated from the time curves for Z-velocity and Z-acceleration were:
1. The moment of MiVZ, defined as the timing after start of therapy of the 
minimum Z-velocity (=  zero Z-acceleration) in years.




3. The moment of MaVZ, defined as timing after start of therapy of 
maximum Z-velocity (=zero Z-acceleration) in years.
4. The magnitude of MaVZ expressed in Z-score per year (SDS/year).
5. The gain in Z-velocity (=  magnitude of MaVZ-MiVZ =  VZ) which is a 
measure of intensity for catch-up growth.
Statistics. The points MiVZ and MaVZ were analysed for the different treatment 
protocols. In addition the Z-values for height at diagnosis at MiVZ and MaVZ were 
compared between the protocols. For statistical analysis Students' t-test was used. 
Significance was accepted for p-value <  0.05.
5.4 Results
The curve of the Z-velocity and the curve of the Z-acceleration of a representative 
case are shown in figure 5.1. In 58 of the 76 patients the Z-velocity decreased during the 
first period of therapy. The Z-acceleration started negative and increased immediately after 
start of therapy. The timing of the start of the positive
Table 5.1: Mean (+SD) for minimal Z-velocity (MiVZ in SDS/yr) and maximal Z-velocity 
(MaVZ in SDS/yr) and VZ (in SDS/yr) for the different treatment protocols.
protocol number of 
patients
MiVZ MaVZ MiVZ MaVZ 
( VZ)
2-5 with CI 41 -0.38 +  0.27 0.25 +  0.17 0.63 +  0.31
6 +  7 
without CI 35 -0.18 +  0.14 0.22 +  0.13 0.41 +  0.21
p-value t-test 0.000 0.508 0.001
CI =  cranial irradiation.
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Z-acceleration, which is the moment of the minimal Z-velocity (MiVZ), could be indicated. 
In 18 of the 76 patients the Z-acceleration was already positive at diagnosis and the Z- 
velocity increased immediately after start of therapy. In these patients the timing of the 
MiVZ was obtained through backward extrapolation.
No difference was noticed in the timing, after diagnosis, of the MiVZ and the MaVZ of 
patients treated according to protocol 6 (without CI but with corticosteroids during 
maintenance therapy) and patients treated according to protocol 7 (without CI and without 
corticosteroids during maintenance therapy). The moment of the MiVZ for these patients 
was 0.02 (SD 0.54) years and the MaVZ 2.44 (SD 0.67) years after start of therapy.
For the irradiated patients (treated according to protocol 2-5) the MiVZ was 0.41 (SD 0.48) 
and the MaVZ 2.99 (SD 0.72) years after diagnosis. The difference in timing of both points 
between the irradiated and the non-irradiated patients was significant (p-values respectively
0.001 and 0.002, t-test). However the time-interval in between MiVZ and MaVZ was 
comparable for all the patients (mean duration 2.5 years, SD 0.5). So the decrease of the Z- 
velocity was significantly prolonged in patients who received CI but the duration of the 
increase in Z-velocity was comparable for both groups.
Analysis of the intensity of catch-up growth didn't show differences between the patients of 
protocol 6 and patients of protocol 7, with the only exception of the Z-velocity at MaVZ 
which was 0.27 SDS/yr (SD 0.11) for patients treated according to protocol 6 and 0.17 
SDS/yr (SD 0.12) of patients of protocol 7 (p =0.017,t-test). Since the differences are only 
marginal it was decided to compare only two different groups of patients during further 
analysis: 1. patients who received CI (protocols 2-5) and 2. patients treated without CI 
(protocols 6 and 7).
The magnitudes of MiVZ and MaVZ are shown in table 5.1 and the values of the SDS for 
height at diagnosis, MiVZ and MaVZ are shown in table 5.2.
Heights of patients at diagnosis were not significantly different. The magnitude of the 
MiVZ of the irradiated patients is, in comparison to the magnitude of the MiVZ of the non­
irradiated patients, significantly lower (table 5.1). However at this point there is no 
difference in height SDS between the irradiated and the non-irradiated patients (table 5.2). 
The magnitude of the MaVZ was comparable for both irradiated and non-irradiated
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Table 5.2: Z-score (+SD) for height at diagnosis, at minimal Z-velocity (MiVZ) and at maximal 
Z-Velocity (MaVZ) for the different treatment protocols.
protocol number of 
patients
diagnosis MiVZ MaVZ
2-5 with CI 41 -0.3 +  1.1 -0.5 +  1.0 -0.7 +  1.0
6 +  7 
without CI 35 -0.2 +  0.9 -0.2 +  0.9 -0.1 +  1.0
p-value t-test 0.466 0.102 0.012
CI =  cranial irradiation.
patients (table 5.1). So despite a lower Z-velocity at MiVZ the irradiated patients are 
capable to increase the Z-velocity to the same maximum as the non-irradiated patients. 
However despite this capacity there is a significant loss in height SDS of the irradiated 
patients at MaVZ (table 5.2).
In table 5.1 the difference ( VZ) is shown between the minimal Z-velocity and the maximal 
Z-velocity for irradiated and non-irradiated patients. The difference for the irradiated 
patients is 0.63 ( +  0.31) SDS/year which is significantly more than the difference for the 
non-irradiated patients: 0.41 ( +  0.21) SDS/year. So the irradiated patients have a 
significant more intensive catch-up growth.
In applying the Kernel estimation in this study, two different band widths (smoothing 
parameters) were used: the 3.1 3.6 band and the 3.8 4.0 band. The sensitivity to band 




After treatment for childhood ALL, CI as a component of CNS prophylaxis is 
significantly associated with reduced final height 67 127. Apart from more severe growth 
retardation during treatment 49,87 and blunted pubertal growth 52,90 patients who received CI 
also have incomplete catch-up growth, while patients treated for ALL without CI, during 
the catch-up growth fully compensate for the preceding growth deficit 4987.
In this study we demonstrated that the decrease of the Z-velocity was significantly longer 
and the MiVZ was significantly lower, in the irradiated patients, as compared to the non­
irradiated patients. The treatment during the decrease of the Z-velocity comprised 
chemotherapy and corticosteroids in all the protocols and only patients treated according to 
protocol 5 received CI during this phase of therapy. This implies that cranial irradiation 
with a dose of 18 Gy has a direct, negative effect on growth velocity and that growth 
retardation due to CI develops in the early phase of therapy. A remarkable finding is that 
after the Z-velocity increased, even the patients who received CI can reach a maximal Z- 
velocity which is comparable to the maximal Z-velocity of patients treated without CI (table 
1). This increase of Z-velocity is a degree for the intensity of catch-up growth. So the 
catch-up growth in patients who received CI is significantly more intensive. Despite a more 
intensive catch-up growth, the height SDS is significantly lower for the irradiated patients 
at MaVZ (table 2). This loss in height SDS despite a more intensive catch-up growth in 
irradiated patients cannot be explained by a difference in duration of catch-up growth as the 
duration of the catch-up growth is comparable for all patients.
The underlying mechanism for catch-up growth has not yet been fully elucidated. From 
animal studies 8494 it has become clear that growth hormone plays a role in the accelerated 
growth during the period of catch-up growth. More recent data suggest that especially the 
frequency of growth hormone pulses may be a factor in triggering catch-up growth 294. It is 
however improbable that disturbance in growth hormone secretion is a causal factor for 
incomplete catch-up growth after CI. Marky et al 83 performed a longitudinal study of
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growth hormone secretion during treatment for childhood ALL. They didn't show any 
difference in the spontaneous GH secretion during treatment between patients who received 
no CI and those who received 18 or 24 Gy CI as CNS prophylaxis.
Crowne et al 30 performed an analysis of 24-hour serum GH profiles using 20-minute 
sampling of 21 longterm survivors of ALL who received CI with a dose of 18 Gy and 23 
normal children. They showed an abnormality of periodicity and a quantitative reduction in 
GH secretion in patients treated for ALL, which appeared to be restricted to puberty. In the 
prepubertal children the spontaneous GH secretion was normal and no significant 
differences in mean number of pulses or mean pulse amplitudes between the irradiated and 
the control groups were found.
The prevailing explanation for catch-up growth involves a central mechanism which relates 
body size to a reference point for target size and accelerates or decelerates growth rate 
accordingly. Experimental data tend to support the hypothesis of a central control of catch­
up growth 94,95. In animal studies it has been demonstrated that irradiation of the head 
results in stunted growth. Stunted head-irradiated rats are capable of catch-up growth after 
fasting, but only to the stunted body-size 9495. This finding suggests that the mechanism 
which recognize normal body size and which determines the limit of catch-up growth is 
reset for a smaller body size by head irradiation. In this study we demonstrated that the 
duration of catch-up growth of patients who received CI is comparable to the duration of 
catch-up growth of the non-irradiated patients and that the catch-up growth in the irradiated 
patients is more intensive. Nevertheless the catch-up growth of the irradiated patients is 
incomplete. These findings support the hypothesis of a reset of the mechanism which 
recognizes normal body size, to a smaller body size by cranial irradiation.
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6.1 Abstract
Statural growth during puberty was studied longitudinally in 28 patients treated for 
acute lymphoblastic leukaemia. All patients received prophylactic cranial irradiation. Age 
at diagnosis was <  7 years, age at final investigation was >  16 years for girls and >  18 
years for boys. Growth was analyzed using the Kernel estimation. In girls the onset of 
puberty and menarche was at a younger age, as compared to reference values, and the 
duration of the pubertal growth spurt was shorter. Compared to early maturing girls growth 
velocity at peak height velocity was lower. This resulted in a final height which was shorter 
than expected on the basis of height standard deviation score before the start of puberty. In 
boys the duration of the pubertal growth spurt was shorter and the height gain during the 
growth spurt less than in the reference population. In both sexes the bone age development 
was accelerated.
6.2 Introduction
Growth disturbances during treatment are frequently reported in children with 
acute lymphoblastic leukaemia (ALL), particularly when they received cranial irradiation
(CI) as central nervous system (CNS) prophylaxis 34,49,68,87,131. Central premature puberty 
and reduction in growth hormone secretion during puberty have also been demonstrated in 
these children 30-73-74-90-105. The combination of early or precocious puberty and growth 
hormone insufficiency may lead to severe growth impairment during puberty causing a 
further reduction in final height. One of the most important markers for early detection of 
puberty is the age at onset of the pubertal growth spurt (PS). The PS starts about one year 
prior to the onset of thelarche in girls 129. A method for a more differentiated analysis of 
growth during puberty and onset of the PS is the statistical concept of the "structural 
average curve", the so-called Kernel estimation 41,42.
With the Kernel estimation, truly longitudinal curves can be obtained for velocity and
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acceleration. From these curves various phases of pubertal growth can be analyzed in terms 
of timing, intensity and duration.
In this paper we present the analysis of the PS of 28 patients (11 boys and 17 girls) treated 
for ALL using the Kernel estimation. Besides, data about final height (FH), age at 
menarche and bone age development of these patients are presented.
6.3 Patients and Methods
Twenty-eight patients (11 boys and 17 girls) treated for ALL at the University 
Hospital Nijmegen, between 1972 and 1980 were included in the study. Age at onset of the 
disease was <  7 years in all patients. Age of final observation was >  16 years for girls 
and >18 years for boys. The patients were treated according to the consecutive protocols 
of the Dutch Leukaemia Working Group. Chemotherapy comprised: induction treatment 
with Vincristine (VCR), Prednisone (Pred.) +  L-Asparaginase and maintenance treatment 
with 6-Mercaptopurine (6-MP) plus Methotrexate (MTX) alternated with VCR, Pred. +  
Cyclophosphamide. Patients received CI with a dose of 24 Gy as CNS prophylaxis and 
MTX plus Pred. intrathecally. None of the patients received either spinal or total body 
irradiation.
Measurements. Height was assessed at 6-12 months' intervals using standard 
anthropometric techniques. To standardize the results and to allow comparison of children 
of different ages and sexes, values for height were transformed into standard deviation 
scores (SDS), using Dutch reference values 112. Final height (FH) was defined at the 
moment that there was a 6-month growth less than 0.2 cm/year and/or at a bone age (BA) 
of 16 years for girls and 18 years for boys. BA was calculated according to Tanner and
Whitehouse 137.
Statistical analysis. For the estimation of velocity and acceleration on the longitudinal
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growth data, the Kernel estimation was used 41,42. Kernel estimation is a smoothing 
procedure using polynomials up to the degree of 7, holding for a pre-chosen band width for 
age. For reasons of comparability the band width applied by Gasser 41 during puberty of
3.1 year (velocity) and 3.6 year (acceleration) was chosen in this study. Velocity and 
acceleration curves were plotted for each child. Extracted from the velocity curve were: the 
age at onset of the PS, defined as the age of minimal velocity (=  zero acceleration) before 
the PS, the age at peak height velocity (PHV), defined as the age of maximal velocity 
(=zero acceleration) during the PS and the velocity (V) and height (H) reached at these 
ages. The time of the end of the PS was extracted from the acceleration curve, and 
expressed as age of maximal deceleration.
Table 6.1: The age, height and growth velocity at the onset of puberty, at peak height velocity 
(PHV) and at the end of PS (pubertal growth spurt), and the final height of girls treated for ALL 







Onset PS 8.9 +  0.2 9.7 +  1.0 p <  0.0001
PHV 10.6 +  0.7 12.2 +  0.8 p <  0.0001
End PS 12.1 +  0.8 13.8 +  0.8 p <  0.0001
Duration PS 3.2 +  0.9 4.1 +  0.5 p <  0.0001
HEIGHT (cm) 
Onset PS 134.6 +  7.1 136.3 +  7.3 p =  0.4
PHV 146.1 +  7.5 150.4 +  6.0 p <  0.05
End PS 155.9 +  7.9 160.6 +  6.0 p <  0.05
Height gain 20.9 +  5.3 24.7 +  2.6 p <  0.0001
GROWTH VELOCITY (cm/year)
Onset PS 5.7 +  1.0 4.8 +  0.6 p <  0.0001
PHV 7.8 +  0.8 7.0 +  1.0 p <  0.0001
FINAL HEIGHT
(cm) 160.8 +  5.8 165.3 +  5.8 p <  0.01
Data are presented as mean +  standard deviation.Reference groups. The Netherlands third nation wide 
survey 112 was used for the SD scores.
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For evaluation of the longitudinal pubertal data two reference groups were used. Age, 
height and velocity data about the PS in boys and girls were compared to the original Swiss 
reference values 43 as no Dutch values are available for the onset of puberty.
Data about PHV, age at menarche, BA and FH were also compared to Dutch reference 
values 104 145. In order to enable this comparison the Kernel estimation was applied to the 
longitudinal growth data of these Dutch references.
Statistical comparison was made using Student's t test. Significance was accepted for p- 
value <  0.05.
6.4 Results
The data on PS of girls treated for ALL compared to Swiss reference values are 
shown in table 6.1. The ages at onset of puberty, at PHV and at the end of PS were 
significantly lower in girls treated for ALL. The duration of PS in girls treated for ALL 
was also significantly shorter. The height at onset of puberty was not significantly different 
in girls treated for ALL. Heights at PHV and at the end of puberty were significantly lower 
in ALL girls compared to Swiss reference values. However, growth 
velocity at the onset of puberty and at PHV was significantly higher in girls treated for 
ALL compared to Swiss girls. This resulted in a final height which was significantly 
different between the two groups. The adult height of normal Dutch girls, however, is
168.3 cm (SD 6.2).
Age, height, growth velocity and BA at PHV of 17 girls treated for ALL compared to 
Dutch reference values are shown in table 6.2. Compared to our Dutch reference group the 
age at PHV of girls treated for ALL was significantly lower. The girls treated for ALL 
were significantly shorter at PHV. Between the two groups there was no difference in 
growth velocity and BA at the time of PHV.
Age, height, growth velocity and BA at PHV of early maturing girls treated for ALL 
compared to early maturing Dutch reference values are also shown in table 6.2. We defined 
early maturing as PHV before the age of 11 years. Thirteen out of 17 ALL girls
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Table 6.2: Age, height, growth velocity and bone age at peak height velocity (PHV) of all girls 
(total) treated for ALL (n=17) compared to Dutch reference values (n=86)[17] and of the early 
maturing girls (n=13) compared to early maturing Dutch references (n=17) [17]. Early maturing 









10.6 +  0.71 
10.3 +  0.6
11.9 +  0.84 
10.7 +  0.3
p <  0.0001 




146.1 +  7.5 
144.7 +  5.7
152.9 +  5.6 
151.8 +  3.5
p <  0.0005 





7.8 +  0.8 
8.0 +  0.6
8.2 +  1.2
9.2 +  1.4
p =  0.1 
p <  0.01
BONE AGE (years) 
Total 
Early
11.2 +  0.9* 
11.1 +  1.0**
11.4 +  0.7 
10.6 +  0.5
p =  0.5 
p =  0.2
Data are presented as mean +  standard deviation, * n =  11, ** n =  9.








12.0 +  0.4 13.2 +  0.4 p <  0.0005
BONE AGE MENARCHE (cm)
12.7 +  0.5 12.9 +  0.4 p =  0.53
HEIGHT MENARCHE (years)
152.5 +  3.0 162.5 +  4.1 p <  0.0005
Data are presented as mean +  standard deviation.
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and 17 out of 86 Dutch reference girls met this criterium. Compared to early maturing 
Dutch girls, age, height and growth velocity of girls treated for ALL were significantly 
different. The ALL girls reached PHV at a younger age, they were shorter and the growth 
velocity was lower at PHV. Again there was no difference in BA between the two groups. 
Table 6.3 shows the age, BA and height at the time of menarche of girls treated for ALL 
compared to Dutch reference girls. The age at menarche of girls treated for ALL was 
significantly lower than that of normal Dutch girls. The BA at menarche was comparable in 
both groups. The height at menarche of girls treated for ALL was significantly shorter than 
that of the Dutch references. In patients treated for ALL the median time interval between 
PHV and menarche was 1.35 years (SD 0.47) and the median growth after menarche was
7.1 cm (SD 2.0), which are both within the normal range.
The data about the PS of boys treated for ALL compared to Swiss reference values are 
shown in table 6.4. There were no differences in the age at onset of puberty, at PHV and at 
the end of the PS, but the duration of the pubertal growth was significantly shorter in boys 
treated for ALL. Height at onset of puberty of boys treated for ALL was not different from 
that of Swiss boys. Height at PHV and at the end of the PS and the height gain during 
puberty were significantly lower in boys treated for ALL. Growth velocity at onset of 
puberty and at PHV was comparable in both groups. Final height of boys treated for ALL 
was significantly shorter. However, final height of normal Dutch boys is 182.0 cm (SD 
6.7). Figure 6.1 shows the difference between BA and calender age (CA) ( +  SEM) of boys 
and girls treated for ALL, from diagnosis to puberty. The difference between BA and CA 
at diagnosis was 0.23 year ( +  0.20). During treatment a retardation in bone maturation 
occurred: BA - CA at the moment of finishing therapy was -0.48 year ( +  0.16). After 
cessation of therapy an acceleration of bone age development occurred: BA - CA before the 
onset of puberty was -0.18 year ( +  0.30). This acceleration continued throughout puberty: 
BA - CA at PHV was 0.43 year ( +  0.26) and at menarche 1.06 year ( +  0.22). The SDS 
for heigth of the 28 patients was -0.51 before the start of puberty. At the moment of PHV 
the SDS for height was declined to -1.48 and at final height the SDS was -1.33.
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Table 6.4: The age, height and growth velocity at the onset of puberty, at peak height velocity 
(PHV) and at the end of PS (pubertal growth spurt) and final height of boys treated for ALL 







Onset PS 11.2 +  0.7 10.9 +  1.1 p =  0.3
PHV 13.7 +  0.6 13.9 +  1.0 p =  0.3
End PS 15.0 +  0.7 15.4 +  0.9 p =  0.1
Duration PS 3.8 +  0.3 4.5 +  0.6 p <  0.0001
HEIGHT (cm) 
Onset PS 140.8 +  6.1 143.6 +  6.8 p =  0.2
PHV 156.0 +  7.7 161.4 +  6.6 p <  0.05
End PS 166.0 +  8.6 172.4 +  6.6 p <  0.05
Height gain 25.9 +  3.1 28.8 +  4.0 p <  0.05
GROWTH VELOCITY (cm/year)
Onset PS 4.2 +  0.6 4.3 +  0.5 p =  0.6
PHV 8.9 +  1.3 8.3 +  0.8 p =  0.1
FINAL HEIGHT (cm)
170.8 +  7.6 177.5 +  6.7 p <  0.01
Data are presented as mean +  standard deviation.
6.5 Discussion
One of the most important late sequelae after treatment for ALL is impaired adult 
height 4968 and it is clear that in a number of patients there is not only a loss in height 
potential during the treatment for ALL but a further loss in height prognosis occurs during 
puberty 90. Especially children treated for ALL with cranial irradiation as CNS prophylaxis 
are at risk for short stature from two mechanisms: growth hormone insufficiency 3090 and
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early pubertal growth 73,74,81. The occurrence of early puberty after CI is well documented 
but less is known about statural growth of these children during puberty. Therefore we 
performed a longitudinal study on growth during puberty in 11 boys and 17 girls treated for 
ALL, using the Kernel estimation 41,42.
Data about PS in boys and girls were compared to Swiss reference values as no Dutch 
references are available for the onset of puberty and on these Swiss data the Kernel 
estimation was applied. Median age of menarche of Swiss girls is 13.4 years 72 and of 
Dutch girls 13.28 years 104 so the timing of puberty of Swiss and Dutch girls is comparable. 
Final height of Swiss girls and boys is less than Dutch children 102112, therefore for height 
data the general Dutch references were used. In our study the onset of puberty was, in 
comparison to Swiss children, significantly earlier in girls treated for ALL but within 
normal limits for boys. This is in agreement with another study 97 that reported that after 
low dose CI (18 - 24 Gy) the high incidence of early puberty was
1.5
- 1,0 -  
- 1.5  -
a b o d e
Figure 6.1: Bone age (BA) minus calender age (CA) ( +  SEM) at diagnosis (a: n=16, 12 ), at the 
end of therapy (b: n=20, 15 ), prepubertal (c: n=11, 8 ), at peak height velocity (d: n=14, 11 ) 
and at menarche (e, n=13).
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predominantly noticed among girls. Damage to the hypothalamic-pituitary axis due to CI 
can cause early secretion of gonadotrophin releasing hormone and be associated with 
precocious puberty 74. There is a sex difference in the response to gonadotrophin releasing 
hormone 74 and it has been postulated that the CNS control on the onset of puberty is more 
easily disrupted in girls than in boys 74 102. We found that the duration of the PS, in both 
boys and girls treated for ALL was significantly less than in healthy Swiss children. The 
consequence was that the height SDS of the 28 patients decreased from -0.51 before the 
onset of puberty to -1.33 at final height.
At peak height velocity growth velocity of ALL girls was comparable to that of Dutch 
girls. However as it is known that the earlier children enter puberty, the greater should be 
their peak height velocity, to compensate for their shorter growth period, we also compared 
the early maturing ALL girls with early maturing Dutch girls. From this comparison we 
learned that growth velocity of the ALL girls was significantly less. Height velocity is 
predominantly controlled by growth hormone pulse amplitude 57. It has been reported that 
the expected increase in growth hormone secretion during puberty is absent in children who 
have undergone low-dose cranial irradiation 30 although in the mentioned study the mean 
pulse amplitudes of children treated with 18 Gy CI were not significantly different from 
normal. We found that in the girls treated for ALL age and height at PHV and menarche 
were significantly different from the mean of the normal Dutch girls. Bone ages at both 
points were not different. In girls treated for ALL growth after menarche was within the 
normal range. So the loss in height potential occurs in the early pubertal growth. This is 
concomitant with the loss of growth velocity in the increment of the early pubertal 
acceleration.
During treatment the difference between BA and CA, in this and another study 134, showed 
a retardation of BA development with a catch-up of BA maturation after cessation of 
therapy. Moreover we showed that a further acceleration of BA development occurred 
during puberty.
It has to be emphasized that the Kernel estimation provides us with a method for more 
differentiated analysis of growth during puberty independent of pubertal characteristics. 
Especially in boys treated for ALL, testicular size as an indicator for the onset of pubertal 
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development is not always reliable as it has been reported that testicular size can be 
influenced by chemotherapy 105.
In conclusion, in girls the onset of puberty occurred at a younger age than in references, 
the duration of PS was shorter, and the BA development was more rapid which resulted in 
further loss in final height. In boys the onset of puberty was at a normal age but the 
duration of PS was shorter and the BA maturation was more rapid also resulting in a loss of 
final height.
A consequence of these conclusions is that the height SDS during puberty, of patients 
treated for ALL, cannot be compared with age matched references without correlation to 
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7.1 Abstract
Weight for height of 92 patients (51 girls and 41 boys) treated for acute 
lymphoblastic leukemia (ALL) was evaluated in a longitudinal study. Fifty-four patients 
received cranial irradiation (CI) with a dose of 18 or 24 Gy and 38 patients did not receive 
CI. Seventy-seven patients were treated according to a normal-risk protocol and 15 patients 
received more intensive chemotherapy according to a high-risk protocol. In most of the 
patients the duration of follow-up was 12 years for irradiated patients and 4.5 years for the 
non-irradiated patients.
Thirty out of 92 patients were treated according to a protocol without CI but with a 
difference in the use of corticosteroids: 19 patients received dexamethasone during the 
remission-induction and maintenance treatment and 11 patients received prednisone.
The influence of dexamethasone versus prednisone, sex, cranial irradiation and high-dose 
versus low-dose chemotherapy on weight for height was evaluated. Patients who received 
dexamethasone showed a significant increase in weight for height immediately after start of 
therapy. In patients who received CI weight for height significantly increased after the first 
year of treatment. The overweight in these patients persisted during the whole follow-up 
period. The weight for height of patients treated with prednisone and of patients who did 
not receive CI was below the mean of the normal population during treatment but was not 
different from normal after cessation of therapy. No difference in weight gain was seen 
between boys and girls and between patients who were treated with high versus normal risk 
protocols.
7.2 Introduction
The last decade many studies have been published on linear growth of children 
treated for ALL concluding that retardation of linear growth during treatment is a common 
observation 17>27>66"68"87 111 120. Data about weight gain in these patients are limited.
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Malnutrition leading to loss of weight, as a consequence of the disease itself or the side- 
effects of chemotherapy, might be one of the causal factors of early growth deceleration. 
Our clinical impression however is that several patients showed excessive weight gain 
during and after treatment. Other authors also noticed obesity in a number of children 
during and after treatment for ALL 1688 118 131 135 155, but it is not clear if all the treatment 
modalities are associated with a higher risk for developing obesity.
In this study we evaluated weight development during and after treatment for ALL in order 
to answer the following questions:
1. Does the Z-score of weight for height decline during the period of treatment of 
children treated for ALL?
2. Is the pattern of body weight development influenced by treatment?
3. Could we identify treatment factors related to the pattern of weight development in 
these patients?
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7.3 Patients and methods
Patients. Ninety-two consecutive patients with ALL treated at the Department of Paediatric 
Oncology of the University Hospital Nijmegen between 1972 and 1988 were included in the 
study. Data about age and sex are shown in table 7.1. Since central nervous system (CNS) 
involvement could cause hypothalamic dysfunction 8, patients with CNS involvement were 
excluded from the study. All patients had entered into first remission within six weeks after 
diagnosis. Patients with relapse of their disease were excluded from the study.
Treatment. Depending on the risk factor of leukemia, patients were divided into two 
groups:
I: Normal-risk leukemia (n=77), defined as leucocyte count in the peripheral blood 
<  50.000/mm3, without mediastinal enlargement, were treated according to the 
consecutive protocols 2,3,5 and 6 of the Dutch Leukemia Working Group.
Protocols 2, 3 and 5 comprised induction treatment with Vincristine (VCR), 
Prednisone (Pred), with or without L-asparaginase (L-Asp) and maintenance 
treatment with 6-mercaptopurine (6MP), methotrexate (MTX) alternated with VCR 
and Pred.
Thirty patients were treated according to protocol 6, 19 of these patients (group Ia) 
received induction treatment with VCR, Dexamethasone (Dexa) 6 mg/m2 and L-Asp 
and maintenance treatment with 6-MP, MTX alternated with VCR, Dexa. Eleven 
patients (group Ib) received the same treatment with only a difference in the 
corticosteroid medication. In these patients Dexa was replaced by Pred. 40 mg/m2, a 
doses nearly equal on basis of glucocorticoid activity.
II: High-risk leukemia (n=15), defined as leucocyte count >  50.000/mm3, and/or 
mediastinal enlargement, were treated according to a high-risk protocol comprising 
induction treatment with cyclophosphamide (Cyclo), VCR, Pred, L-Asp, and 
adriamycine (Adria). The maintenance treatment consisted of 6-MP, MTX and 
cyclo alternated with VCR, Pred, Adria and Cytosine-Arabinoside (Ara-C).
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Table 7.2: Number of patients during follow-up (n=92). A number of the initial values was missing. At 3 months after diagnosis all 
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No irradiation 
- protocol 6: dexa
group Ia
14 19 19 19 18 13 7
- protocol 6: pred
group Ib
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Chapter 7
Depending on the method of CNS prophylaxis, patients were divided in two groups:
A: Fifty-four patients treated between 1972 and 1984 received cranial irradiation (CI); 
37 patients with a dose of 24 Gy in 13 fractions over 17 days and 5 doses MTX and 
Pred intrathecally (i.t.) and 17 patients received 18 Gy CI in 10 fractions over 14 
days and 5 doses MTX and Pred i.t. (1972 - 1984). None of the patients received 
spinal irradiation. The timing of the CI was 5 to 6 weeks after diagnosis for all 
patients. Duration of follow-up up to 12 years.
B: Thirty-eight patients treated between 1984 and 1988 did not receive CI. The CNS 
prophylaxis in these patients consisted of high-dose MTX intravenously combined 
with MTX and Pred i.t. During maintenance treatment 8 doses of MTX, Pred and 
Ara-C were given i.t. Duration of follow-up up to 4.5 years.
Forty-three out of 77 patients with normal-risk and 11 out of 15 patients with high-risk 
leukemia received CI. The number of patients during the follow-up period is shown in table
7.2.
Measurements and methods. Patients heights and weights were measured by experienced 
staff. During the two years of treatment patients were measured 8 to 12 times per year and 
during the years of follow-up 1 to 4 times per year. Weight for height was studied. In order 
to compare the patients group with the general population Z-scores were calculated for 
weight for height using Dutch reference values 112. The Z-score is defined as the difference 
between a patients weight and the stature and sex appropriate mean divided by the 
corresponding standard deviation. Weight for height is known to be positively skewed 
distributed, therefore a log-transformation after translation ln(x-c) was applied comparable 
to the method developed by van 't Hof et al 146. The translation (c) is stature- and sex- 
dependent. The translation was chosen so that a symmetric distribution with regard to the 
P10, P50 and P90 was obtained. The transformed distribution was used for the calculation of 
the Z-scores. Estimates of the Z-scores at regular time intervals were obtained by 
interpolation in the individual Z-score curves.
Statistical analysis. Statistical comparisons were made using student-t-test and analysis of 
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variance. Significance was accepted for p value <  0.05.
7.4 Results
In order to investigate the influence of different glucocorticoids on body weight 
development we compared the Z-scores of weight for height of patients treated according to 
protocol 6 of the Dutch Leukemia Working Group with dexamethasone (group Ia) with the 
Z-scores of patients who received prednisone instead of dexamethasone (group Ib) (figure
7.1). The chemotherapy in both groups was the same and neither of these patients received 
cranial irradiation. At diagnosis the Z-score of weight for height of group Ia was -0.1 +
1.3 ( +  standard deviation) and of group Ib -0.4 +  1.1. This difference is not significant. 
Three months after start of therapy the Z-score was 0.5 +  1.1 for group Ia
0 1 2
f o l l o w - u p  a f te r  diagnosis [years]
Figure 7.1: Mean Z-scores ( +  SEM) of weight for height of patients treated for ALL according to 
protocol 6 of the Dutch Leukemia Working Group. The patients receiving dexamethasone (solid 
line), n=19, are compared with the patients receiving prednisone (broken line), n=11. * =  
p < 0 .05 , ** p < 0 .005 , indicating the t-test significance level.
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and -0.8 +  1.4 for group Ib. The difference is significant (p =0.01). In order to investigate 
whether the baseline difference in Z-scores of +0.3 in the two groups influenced the 
significance at three months and to examine whether the difference at three months could be 
an artifact due to the 5 and 3 patients that were added to each group, respectively, we 
calculated the change from the baseline: Z ( Z =  Zx - Z0, Zx is the Z-score at 3 months 
and Z0 is the Z-score at diagnosis) of the 14 and 8 patients at three months. The Z of the 
14 patients treated with dexamethasone was 0.5 +  0.8 and of the 8 patients treated with 
prednisone was -0.2 +  0.8. This difference is also significant (p=0.04). A significant 
difference between the two groups persisted during the whole follow-up period of 4.5 
years.
As treatment with dexamethasone has a clear influence on weight for height, 19 patients 
treated with dexamethasone, all from protocol 6, were excluded from further analysis.
By means of 2-way ANOVA the influence of sex and cranial irradiation on weight for
follow-up after diagnosis [years]
Figure 7.2: Mean Z-score ( +  SEM) of weight for height of patients treated for ALL with 
prophylactic cranial irradiation (solid line), n=54, or without prophylactic cranial irradiation 
(broken line), n=19. All patients received prednisone as corticosteroid. * =  p <0.05, ** p <0.01, 
indicating the ANOVA significance level.
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Figure 7.3: Mean Z-scores ( +  SEM) of weight for height of the irradiated patients with follow-up 
of 12 year.
height was studied. The Z-score of weight for height of the irradiated group compared with 
the Z-scores of patients who did not receive CI are shown in figure 7.2. No significant 
differences between the groups were shown during the first year of therapy. At two and 
four years from diagnosis the Z-scores were respectively -0.2 +  1.1 and 0.0 +  1.2 for the 
non CI group and 0.4 +  1.1 and 0.7 +  0.9 for the patients who received CI. These 
differences are significant, p values respectively 0.04 and 0.05.
Figure 7.3 shows the Z-scores of weight for height of the irradiated patients during the 
follow-up period of 12 years. At the end of treatment, 2 years after diagnosis, the Z-score 
was 0.4 +  1.1. Two years after cessation of therapy the Z-scores was more positive: 0.7 +  
0.9. The Z-score remained above the mean of the normal population during the whole 
period of follow-up. Z-score 12 years after diagnosis: 0.4 +  1.0.
No differences in body weight development were noticed between boys and girls and 
between patients treated according to a normal-risk protocol versus patients treated 




At diagnosis the weight for height of patients in this study was not significantly 
different from the weight for height of the normal population. All patient groups, with 
exception of the group of patients treated with dexamethasone, showed loss of weight 
during the first three months of treatment. The underweight of these patients during this 
phase of therapy could have attributed to the impairment of height growth, which was also 
demonstrated in our patients 49. During the next three to six months, weight for height of 
the patients increased to normal, however, weight for height of the irradiated patients 
further increased during the second year of treatment and the first year after cessation of 
therapy. After this period the weight for height of these patients stabilized but the Z-score 
remained above the mean of the normal population during the whole follow-up.
All studies 1688 118 119 131 135 155 but one 149 with respect to weight reported an increased weight 
velocity during or after treatment for ALL. Different factors as lack of physical exercise 
and poor dietary habits 118,155 have been suggested to contribute to the excess weight gain in 
these patients who have suffered a serious illness. In this study, however, there is clear 
evidence that two treatment modalities: cranial irradiation and treatment with 
dexamethasone are associated with excessive weight gain. Patients treated without CI and 
patients who received prednisone instead of dexamethasone showed normal weight 
development during the second year of therapy and after finishing treatment. Another study 
155 has also identified CI as a risk factor for developing obesity. CI is also associated with 
impaired height growth 119,155. Some authors 119,155 suggested that compromised height is a 
major contributor of obesity and occurs when height compromise is not accompanied by 
parallel weight compromise. However, in the study of Schell et al. 119 patients receiving 
craniospinal irradiation were shown to be at increased risk for abnormally short stature but 
not for obesity. This finding suggests that other factors than just compromised height are 
responsible for obesity.
It is well known that especially endocrine disorders causing blunted growth are attended
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with overweight such as hypothyroidism, hypercortisolism and growth hormone deficiency. 
Hypothalamic-pituitary dysfunction involving corticotrophin and thyroid stimulating 
hormone has not been demonstrated in children treated for ALL 98 133. The impaired linear 
growth seen in children after CI has been thought to be attributed to minor abnormalities in 
the secretion of growth hormone 30,31. Dacou-Voutetakis et al. 31 showed transient 
alterations in growth hormone secretion early after CI in children treated for ALL. A 
quantitative reduction in growth hormone secretion during puberty of children treated for 
ALL has been shown by Crowne et al. 30, suggesting that CI causes damage to the 
hypothalamic-pituitary axis affecting the secretion of growth hormone. The hypothalamus 
seems more vulnerable to radiation damage than the anterior pituitary 29. Hypothalamic 
damage perse may cause obesity, however, the reported cases of hypothalamic obesity in 
children with ALL have always been demonstrated in patients with leukemic infiltration of 
the brain 8. Studies on growth hormone profiles of children after low-dose CI 30 or total 
body irradiation 130 show a disturbance of frequency modulation of growth hormone 
secretion. Both studies 30 130 postulate that disturbance of somatostatin secretion is the 
underlying mechanism for this observation. Our hypothesis is that neurosecretory 
dysfunction is responsible for the excessive weight gain in patients who received CI.
Excess of weight gain during and after treatment for ALL is also shown in children treated 
with dexamethasone, whereas children treated with prednisone in an equivalent dose 
showed normal weight development. Besides the well-known peripheral effects of 
corticosteroids on growth and weight 3, glucocorticoids also exert an effect on the 
regulation of growth hormone secretion 46. High dose prednisone (40 mg /  m2 /  day) used in 
the treatment for ALL resulted in decreased growth hormone secretion during deep sleep as 
well as in response to arginine, insulin and growth hormone releasing hormone 
administration 19. Dexamethasone in a dose of 10 mg /m 2 /  day completely suppressed the 
spontaneous growth hormone secretion in patients treated for ALL 83. The inhibiting action 
of corticosteroids on growth hormone responses seems to be mediated by an enhancement 
of the somatostatin effect at the pituitary level 46.
Increase of weight in patients treated with dexamethasone is immediately shown after start 
of treatment, while all other patients show loss of weight during this phase of intensive
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chemotherapy. The loss of weight of most patients during the first months of therapy is 
presumably due to the side effects of cytotoxic drugs such as nausea and vomiting resulting 
in inadequate nutrition. Dexamethasone and not prednisone appears to circumvent this 
action and leads immediately after the start of treatment to excessive weight gain. It could 
be speculated that excessive weight gain after treatment with dexamethasone is also a 
consequence of neurosecretory dysfunction and that dexamethasone exerts a stronger 
central effect than prednisone.
In patients who had undergone CI the overweight persisted during the whole follow-up 
period of twelve years. In view of the age distribution of the patients included in the study 
we may conclude that, compared to age and height matched controls, the overweight of 
these patients persisted during puberty and adolescence. It is not yet clear if overweight in 
the dexamethasone treated patients also persists during such a long period of time. 
Dexamethasone has proven in in-vitro studies to have a stronger antileukemic effect than 
prednisone 64. So, in the future, dexamethasone could become a more common drug in the 
treatment of ALL. As obesity has serious long-term psychological and medical 
consequences, awareness of this potential complication could contribute to its prevention.
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The regulation of human growth, from infancy to adulthood, is a complex mecha­
nism involving many different hormones and growth factors acting at different levels: 
central, systemic and at the level of the growth plate. In the regulation of growth during 
childhood three different phases can be distinguished: growth during infancy which is 
mainly regulated by nutrition and local growth factors, growth of midchildhood regulated 
by growth hormone and thyroid hormone and growth during puberty which is not only 
dependent of growth hormone and thyroid hormone but also of sex steroids. This remark­
able integrated process of growth regulation will, under normal conditions, result in growth 
according to a predominated growth curve, a curve which is genetically determined.
In view of the complexity of the mechanism it is not astonishing that enviromental factors 
and diseases in childhood can cause a disturbance of this process resulting in growth retar­
dation.
Growth retardation, a deflection away from the normal growth curve, is a frequent side- 
effect in children treated for ALL. Many causal factors can contribute to the growth retar­
dation in these patients. The disease ALL itself originates in the bone-marrow and could 
therefore interfere with control of growth at the level of the growth plate as the 
hematopoietic bone-marrow plays a role in bone cell development. Each of the three treat­
ment modalities applied in the treatment of ALL: chemotherapy, radiotherapy and 
corticosteroids can have an influence on growth, while side-effects of chemotherapy and 
radiotherapy such as nausea and vomiting can lead to malnutrition which influences growth. 
In this thesis we focussed our attention to 1. the growth of children during and after treat­
ment for ALL, by means of biometry of growth data and 2. the discrete contribution to 
growth retardation of the different causal factors.
When designing a study on growth and especially on disturbed growth where multiple
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causal factors can add to the growth retardation, it is important to standardize the results. 
The use of standard deviation scores not only enables comparison between sexes and ages 
but also between different studies.
For the inclusion criteria of a group of children in a growth study, the three different 
phases of growth during childhood have to be taken into account, notably the pubertal 
growth spurt can interfere with catch-up growth or mask growth retardation.
The design of a longitudinal study is preferred above a cross-sectional study as a longitudi­
nal study reveals individual differences in growth velocity and in the timing of particular 
phases of growth such as the pubertal growth spurt.
Biometry of the longitudinal growth data of patients treated for ALL, with cranial 
irradiation as central nervous system prophylaxis, showed a SDS for height which de­
creased during the first year of treatment, followed by a period of parallel growth.
After cessation of therapy the SDS for height increased, but this catch-up growth was 
incomplete (chapter 2). After catch-up growth again a period of parallel growth occurred 
till puberty. During puberty a further decrease of the SDS for height was noticed, caused 
by an insufficient growth spurt, resulting in a significant loss of height SDS at final height 
(chapter 6).
The SDS for height of patients treated without cranial irradiation also decreased during the 
first six months of therapy followed by a period of parallel growth but these patients 
showed a complete catch-up growth after cessation of therapy (chapter 2). To date no 
sufficient data are obtained of these patients to describe growth during puberty.
The medical history of a child presenting with ALL is usually short with complaints exist­
ing no longer than several weeks to months. In all studies concerning growth during treat­
ment for ALL, the heights of the patients at diagnosis are not significantly different from 
the mean height of the normal population. From these studies the conclusion has been 
drawn that the influence of the disease ALL itself is minimal. In chapter 4 of this thesis we 
did not only study the attained height of the patients but also growth acceleration and
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growth velocity. From this study we learned that the growth velocity of a child with ALL is 
extremely low at diagnosis. Immediately after start of the remission-induction therapy with 
chemotherapy and corticosteroids, acceleration of growth with increase in growth velocity 
was demonstrated despite the growth suppressive effects of the treatment instituted. This is 
a clear indication that there is an influence on growth of the disease ALL which is not 
surprising in view of the involvement of the bone-marrow function in the growth of the 
bone.
The duration of the low growth velocity due to ALL is apparently not long enough to cause 
a significant decrease in height SDS before the diagnosis of ALL is made. In most of the 
children with ALL, complete remission with restoration of the bone marrow function is 
achieved within six weeks after start of therapy. So although there is a clear influence of 
ALL on growth the duration of this influence is limited.
Despite acceleration of growth i.e. an increase in growth velocity immediately after start of 
therapy, which continued throughout the whole period of treatment, the growth velocity of 
the patients with ALL remained below the growth velocity of the normal population during 
the first period of treatment, resulting in a significant decrease of height SDS (chapters 4 
and 2).
The suppression of the increase in growth velocity during this phase of therapy is probably 
a consequence of the growth suppressive effects of the treatment modalities.
The remission-induction therapy in children with ALL always comprises chemotherapy and 
corticosteroids. The growth suppressive effects of corticosteroids are well known and the 
possibilities of interferences of corticosteroids, in the complex mechanism of growth regu­
lation, are numerous. If there is an additional growth suppressive effect of chemotherapy 
during this early phase of therapy could not be investigated as all patients received during 
this phase the combination of chemotherapy and corticosteroids. Although little is known 
about the influence of chemotherapy on growth, it can be assumed that chemotherapy, in a 
certain dosage, will have a growth suppressive effect, as chemotherapy causes aplasia of
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the bone-marrow. Bone-marrow aplasia could affect growth factors which originate from 
the bone-marrow cells and are involved in growth of the bone. Besides chemotherapy might 
exert a direct growth suppressive effect at the level of the growth plate. In children treated 
for ALL multiple growth arrest lines are seen on the X-ray of the bone.
In this thesis, indeed, a clear influence of chemotherapy on growth could be demonstrated. 
In chapter 2 a group of patients was identified with a significantly more severe growth 
retardation during treatment. These patients received cranial irradiation as central nervous 
system prophylaxis and chemotherapy and corticosteroids during the remission induction 
therapy but because of the fact that they had a high risk leukemia these patients received 
high dose chemotherapy. The growth of these patients was significantly worse than of 
patients treated with cranial irradiation and normal dose chemotherapy. In patients who 
were not irradiated no different influences of high dose versus normal dose chemotherapy, 
on growth, were noticed. Herewith we demonstrated that there is a synergistic negative 
effect on growth of high dose chemotherapy and cranial irradiation.
From the results described in chapter 3 we learned that the growth suppressive effect of 
chemotherapy with 6-Mercaptopurine and Methotrexate is as strong as the growth suppres­
sive effect of the same chemotherapy in combination with corticosteroids.
In children who received cranial irradiation as a part of their treatment three moments of 
blunted growth could be detected.
- During the first year of therapy growth retardation in these children was 
more severe than in children who didn't receive cranial irradiation (chapter 
2). The pathogenesis of this early growth retardation is unknown. A well 
known side-effect of cranial irradiation is growth hormone insufficiency or 
deficiency but in studies that analysed growth hormone secretion in patients 
who received cranial irradiation it was demonstrated that growth hormone 
secretion during this phase of therapy was normal.
- In contrast to patients who were not irradiated the catch-up growth of pa­
tients who received cranial irradiation was incomplete (chapter 2). In the
113
Chapter 8
study concerning catch-up growth (chapters 4 and 5) it was shown that the 
duration of catch-up growth was not different for patients treated with and 
without cranial irradiation. Besides the catch-up growth was even more 
intensive in the irradiated patients. From these findings it was hard to under­
stand that especially the irradiated patients had an incomplete catch-up 
growth. However these results do support the hypothesis that the central 
mechanism which recognizes normal body size and which determines the 
limit of catch-up growth, is reset for a smaller body size by cranial irradia­
tion.
- A third moment of growth retardation after cranial irradiation is the phase of 
the pubertal growth spurt which is described in chapter 6. In girls who re­
ceived cranial irradiation the onset of puberty and the menarche were signifi­
cantly earlier than in the reference population. The causal factor for this 
early onset of puberty is thought to be cranial irradiation which caused dam­
age to the hypothalamic-pituitary axis leading to early secretion of 
gonadotrophin releasing hormone and early start of puberty. There is a sex 
difference in the response to gonadotrophin-releasing hormone and it has 
been postulated that the control mechanism of the central nervous system, 
for the onset of puberty is more easily disrupted in girls than in boys. This 
could be an explanation for the observation that only in girls the onset of 
puberty is early after cranial irradiation. For both boys and girls it turned out 
that the duration of the pubertal growth spurt was shorter, the bone-age 
development was accelerated and the height gain during the growth spurt 
was less than in the reference population. The diminished growth during 
puberty of patients who received, at a younger age, cranial irradiation during 
the treatment for ALL can be due to a relative growth hormone deficiency or 
growth hormone insufficiency, developed as a late side effect of cranial 
irradiation.
During the follow-up of patients who received cranial irradiation at a younger age the
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aspects of early pubertal development and accelerated bone-age development during pu­
berty must be taken into account. It is important not only to measure height and weight but 
also to be aware of pubertal development and to analyse bone-age. Height measured during 
the follow-up period always must be related to the development of pubertal characteristics 
and bone age development.
In patients who have a significant loss in height SDS due to treatment for ALL, an indica­
tion can arise for treatment with growth hormone during puberty. It is important to start 
such a treatment early, or in combination with gonadotrophin-releasing hormone agonists, 
as the time over which the treatment can be applied is limited.
In the literature there is much debate over the different influences on growth of cranial 
irradiation with a dose of 18 or 24 Gy. In our study described in chapter 2 we didn't find a 
significant difference in height SDS, during and 2.5 years after treatment, of children 
treated with 18 or 24 Gy. Considering our observation of a synergistic negative effect on 
growth of high dose chemotherapy and cranial irradiation (chapter 2) we would emphasize 
that the (additional) influence of chemotherapy on growth should not be ignored in studies 
focussed on the comparison the different effects of 18 and 24 Gy. The duration or intensity 
of chemotherapy could be confounding factors.
Although treatment modalities played an important role in growth retardation of patients 
treated for ALL, from the velocity and acceleration studies in chapters 4 and 5 we may 
conclude that the start of the catch-up growth is independent of the moment of cessation of 
therapy.
The nutritional status of a child can have an influence on growth. Nausea and vomiting, as 
side effects of chemotherapy and radiotherapy, can cause malnutrition in cancer patients. At 
present tube-feeding is often used to prevent patients for malnutrition but before tube­
feeding was introduced in the supportive care of cancer patients, malnutrition could be an 
additional factor for diminished growth during treatment. In our study on weight for height 
(chapter 7) we demonstrated that all patients, with exception of patients who received
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dexamethason during the remission induction phase, had a significant loss of weight during 
the first three months of therapy. In this phase underweight could have an influence on 
statural growth. During the next months weight for height increased to normal but for 
patients who received dexamethason and patients who were irradiated, weight for height 
increased further and the SDS for weight for height remained above the mean of the normal 
population during the whole period of follow-up.
Next to the fundamental property of human growth that height proceeds according to a 
predicted growth channel, it is a common experience that, under normal conditions, organ­
isms follow predictable patterns of proportionate growth for height and weight. Data from 
animal studies favour the existence of a proportionate growth control located in the brain. 
Especially endocrine disorders such as hypothyroidism, hypercortisolism and growth 
hormone deficiency, that cause blunted growth, can alter body proportions. Discordant 
growth in body weight and tail length has occurred in neonatal rats which have been stunted 
by bilateral irradiation of the head. In patients who received either dexamethason or cranial 
irradiation as a part of their treatment, the persistance of the overweight during the whole 
period of follow-up, could indicate a damage to or reset of the central mechanism which 
regulates proportional growth.
In summary the influences of the studied modalities on growth:
- The disease ALL exerts its effect on growth during the early phase of ther­
apy, probably before complete remission is achieved.
- Chemotherapy and corticosteroids are additional causal factors for growth 
retardation during the first six months of therapy.
- Chemotherapy plays a role in the inhibition of catch-up growth during the 
phase of maintenance therapy




- Cranial irradiation exerts its negative effect on growth during different 
phases of growth. During the first six to twelve months of therapy cranial 
irradiation causes a more severe growth retardation. The catch-up growth is 
incomplete. In girls early pubertal development appears and the pubertal 
growth spurt in boys and girls is insufficient.
- With exception of patients who received dexamethason, all patients have 
underweight, as reflection of a bad nutritional status, during the first three 
months of therapy. During this period underweight could attribute to growth 
retardation.
In general it can be concluded that risk factors for significant loss of height at final height 
are: cranial irradiation in combination with high dose chemotherapy, early onset of puberty 
in girls and small height at onset of puberty of patients who received cranial irradiation. 
During the follow-up of patients who have been treated for acute lymphoblastic leukemia 
these factors have to be taken into account.
In this thesis a survey of the biometry of growth of children treated for ALL is presented. 
The conclusions of the studies urge the need for further investigations to the underlying 
mechanisms for the development of growth retardation. The possibilities of interferences in 
the complex mechanism of the regulation of growth are numerous and will be different for 
the different entities. It is already known that cranial irradiation can cause growth hormone 
insufficiency or growth hormone deficiency, which only occurs as a late side effect. The 
underlying mechanism for the early growth retardation in children treated for ALL is 
unknown. Besides possible disturbances in the endocrine control of growth there is also a 
possibility that disturbances in the local control of growth, at the level of the growth plate, 
already exists at diagnosis of ALL or could develop during treatment with cranial irradia­
tion, chemotherapy and corticosteroids.
In our department a study is ongoing to the endocrine control of growth of children during 








The incidence of childhood cancer is one per 10.000 children in the age group of 
0-15 years. Acute lymphoblastic leukaemia (ALL) is the most frequent diagnosed malig­
nancy accounting for 30% of all childhood malignancies. Introduction of central nervous 
system (CNS) prophylaxis in the treatment for ALL and intensification of therapy have 
resulted in a survival rate of +  70%. Many of these survivors have to face late side 
effects. One of the most important late effects after treatment for ALL is growth retarda­
tion. Causal factors which could attribute to growth retardation after treatment for ALL 
are the disease ALL itself, chemotherapy, radiotherapy, corticosteroids and underweight 
as a sign of bad nutrition due to the disease ALL and to nausea and vomiting during 
treatment. In the studies presented in this thesis we performed a retrospective, longitudi­
nal study to different influences on growth of the separate entities.
C hapter one presents an overview of the regulation of normal human growth and possi­
ble influences on that related to ALL. From this the aim of the study was defined and the 
studies reported in this thesis were described. The aim of the study is to investigate the 
influence on growth of the distinct entities: the disease ALL itself, nutritional status 
reflected by weight, chemotherapy, radiotherapy and corticosteroids in order to identify 
risk factors in the treatment for ALL which are responsible for growth retardation.
In chapter two we describe the statural growth, from diagnosis to 2.5 years after 
cessation of therapy, of 85 children treated for ALL. To avoid the influence of the 
pubertal growth spurt all patients were prepubertal during the study period. According to 
the central nervous system prophylaxis, the patients were divided into three groups: 
patients who received cranial irradiation with a dose of 24 Gy, patients who received 
cranial irradiation (CI) with a dose of 18 Gy and patients who were not irradiated. 
According to the risk of leukaemia patients were divided into normal-risk and high-risk 
groups. All patients show a decrease of the standard deviation score (Z-score) for height
120
Summary
during the first 6-12 months of therapy. The patients who received cranial irradiation 
have a significant further decline of the Z-score for height. After a period of parallel 
growth all patients show catch-up growth. In contrast to the non-irradiated patients the 
catch-up growth of the irradiated patients is incomplete.
There is no difference in growth pattern between patients who received CI with 18 versus 
24 Gy and chemotherapeutic treatment according to high-risk versus normal-risk 
protocols. However a synergistic negative effect of more intensive chemotherapy and CI 
on growth is demonstrated.
In chapter three we describe growth during maintenance therapy. Until 1988 
maintenance therapy comprised chemotherapy and corticosteroids. The patients treated 
according to these protocols didn't show catch-up growth during this phase of therapy. 
The protocols which were applied after 1988 only comprised chemotherapy during 
maintenance therapy. The expectation was that if corticosteroids would be the major 
causal factor for the inhibition of catch-up growth, catch-up growth could occur during 
the phase of maintenance therapy in those patients who only received chemotherapy.
In this study we compare the Z-score for height during maintenance therapy of 2 groups 
of prepubertal patients; one group received chemotherapy and corticosteroids and the 
other group only received chemotherapy during maintenance therapy. No significant 
difference in Z-score for height is noticed between the two groups, so it can be conclu­
ded that the growth suppressive effect of chemotherapy with 6-Mercaptopurine and 
Methotrexate is as strong as the growth suppressive effects of the same chemotherapy in 
combination with corticosteroids. So at least chemotherapy alone has a growth suppressi­
ve effect.
In the chapters four and five we describe catch-up growth. After a period of decrease of 
the Z-score for height and a period of parallel growth, all patients show an increase of 
the Z-score for height. For the patients who were not irradiated the catch-up growth is 
complete, however patients who received CI have an incomplete catch-up growth. At this 
point the irradiated patients loose height with consequences for final height. By means of
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analysing growth velocity, growth acceleration, Z-velocity and Z-acceleration curves we 
investigated the influence of different treatment modalities: chemotherapy, radiotherapy 
and corticosteroids on catch-up growth.
In chapter 4 the timing and in chapter five the intensity of catch-up growth is described. 
At diagnosis of ALL the growth velocity of the patients is low. Growth accelerates 
immediately after start of treatment resulting in an increase in growth velocity. From this 
observation we may conclude that there is an influence of the disease ALL on growth. 
Despite an increase of growth velocity after start of therapy and a further increase in 
growth velocity during the whole period of therapy, an increase in Z-score for height is 
noticed not before the Z-velocity is positive. So the start of the positive Z-velocity is the 
start of the catch-up growth. For the irradiated patients the moment of start of the positi­
ve Z-velocity is significantly later than for the non-irradiated patients. Although the start 
of the catch-up growth for the irradiated patients is about the moment of cessation of 
therapy from this study it is clear that the moment of start of catch-up growth, is inde­
pendent of the moment of cessation of therapy. The start of the catch-up growth coinci­
des accidently with the cessation of therapy. The duration of catch-up growth is compara­
ble for all patients.
The intensity of catch-up growth is defined as the distance between the minimal and the 
maximal Z-velocity. The minimal Z-velocity is significantly lower for the irradiated 
patients and the maximal Z-velocity is comparable for all patients. So catch-up growth is 
more intensive in the irradiated patients.
The observations that the timing of catch-up growth is comparable for irradiated and 
non-irradiated patients and that for irradiated patients the catch-up growth is more inten­
sive, while the catch-up growth in irradiated patients is incomplete, support the hypothe­
sis that cranial irradiation causes a reset of the central mechanism, which recognizes 
normal body size, to a smaller body size.




In chapter 6 growth during puberty is described of 11 boys and 17 girls. All patients 
received cranial irradiation with a dose of 24 Gy as CNS prophylaxis. The age at diagno­
sis for ALL was below 7 years, the age at final investigation was above 16 year for girls 
and above 18 years for boys. In girls the onset of puberty and menarche is at a younger 
age as compared to reference values and the duration of the pubertal growth spurt is 
shorter. Compared to early maturing girls, the growth velocity at peak height velocity is 
lower. This results in a final height which is shorter than expected on the basis of the 
height SDS before the start of puberty. In boys the duration of the pubertal growth spurt 
is shorter and the height gain during the growth spurt less than in the reference 
population. In both sexes the bone age development is accelerated.
In chapter 7 a longitudinal study to weight for height of 92 patients treated for ALL is 
described. Fifty-four patients received CI with a dose of 18 or 24 Gy and 38 patients 
didn't receive CI. Seventy-seven patients were treated according to a normal-risk proto­
col and 15 patients received more intensive chemotherapy according to a high-risk proto­
col. In most of the patients the duration of follow-up was 12 years for irradiated patients 
and 4.5 years for the non-irradiated patients. Thirty of 92 patients were treated according 
to a protocol without CI but with a difference in the use of corticosteroids: 19 patients 
received dexamethason during the remission-induction and maintenance treatment and 11 
patients received prednisone. The influence of dexamethasone versus prednisone, CI and 
high-dose versus low-dose chemotherapy on weight for height is evaluated.
Patients who received dexamethasone show a significant increase in weight for height 
immediately after start of therapy. In patients who received CI, weight for height signifi­
cantly increases after the first year of treatment. The overweight in these patients persists 
during the whole follow-up period. The weight for height of patients treated with predni­
sone and of patients who didn't receive CI is below the mean of the normal population 
during treatment but is not different from normal after cessation of therapy. No differen­
ce in weight gain is seen between boys and girls and between patients who were treated 
with high versus normal risk protocols.
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The conclusions of the studies presented in this thesis are discussed in chapter 8. In 
summary the conclusions are: the disease ALL exerts its effect on growth during the 
early phase of therapy probably before complete remission is achieved. Additional causal 
factors for growth retardation during the first six months of therapy are chemotherapy 
and corticosteroids. Chemotherapy plays a role in the inhibition of catch-up growth 
during the phase of maintenance therapy. High dose chemotherapy and cranial irradiation 
have a synergistic negative effect on growth. Cranial irradiation exerts its negative effect 
on growth during different phases of growth. During the first six to twelve months of 
therapy cranial irradiation causes a more severe growth retardation. The catch-up growth 
is incomplete. In girls early pubertal development appears and the pubertal growth spurt 
in boys and girls is insufficient. Underweight as a reflection of a bad nutritional status 
could attribute to the growth retardation during the first three months of therapy as 










De incidentie van kanker op de kinderleeftijd is één per 10.000 kinderen in de 
leeftijd van 0 - 16 jaar. In 30% van alle oncologische aandoeningen is er sprake van 
acute lymfatische leukemie (ALL). ALL is daarmee de meest voorkomende maligniteit 
op de kinderleeftijd. Na de introductie van centraal zenuwstelsel (CZS) profylaxe in de 
behandeling van ALL en intensivering van behandeling zijn de genezingskansen van 
kinderen met ALL gestegen tot +  70%. Echter veel patiënten die genezen zijn van ALL 
hebben late gevolgen. Eén van de meest voorkomende bijwerkingen na behandeling voor 
ALL is het achterblijven in groei.
Oorzakelijke factoren die kunnen bijdragen aan groeiachterstand na behandeling voor 
ALL zijn: de ziekte ALL zelf, chemotherapie, radiotherapie, het gebruik van 
corticosteroïden en een slechte voedingstoestand als gevolg van de ziekte ALL en ten 
gevolge van misselijkheid en braken als bijwerkingen van de behandeling. In dit proef­
schrift worden retrospectieve, longitudinale studies beschreven naar de afzonderlijke 
bijdrage van de verschillende oorzakelijke factoren aan de groeiachterstand na behande­
ling voor ALL.
In hoofdstuk 1 wordt een overzicht gegeven van de regulatie van normale groei en de 
mogelijke invloeden daarop van de ziekte ALL en van de behandelingsmodaliteiten die 
worden toegepast bij de behandeling van ALL. Hieruit werd het doel van het onderzoek 
gedefiniëerd. Het doel van het onderzoek is het analyseren van de invloed op de lengte- 
groei van de verschillende factoren: de ziekte ALL, gewicht als een maat voor de voe­
dingstoestand, chemotherapie, bestraling en therapie met corticosteroïden. Daarbij komt 
de vraag of er bepaalde risicofactoren zijn die verantwoordelijk gesteld kunnen worden 
voor het ontstaan van een groeiachterstand na behandeling voor ALL?
In hoofdstuk 2 wordt de lengtegroei beschreven over de periode vanaf diagnose tot 2,5 
jaar na het staken van de therapie van 85 patiënten die behandeld zijn voor ALL. Om de
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invloed van de puberteitsgroeispurt te vermijden werden alleen patiënten bestudeerd die 
prepuberaal waren tijdens de studie periode. Afhankelijk van de CZS profylaxe werden 
de patiënten ingedeeld in 3 groepen: patiënten die schedelbestraling kregen met een dosis 
van 24 Gy, patiënten die schedelbestraling kregen met een dosis van 18 Gy en patiënten 
die geen schedelbestraling kregen. Afhankelijk van de risicofactor van de leukemie 
werden patiënten verdeeld in een groep met normaal risico en een met hoog risico. Bij 
alle patiënten wordt een significante daling gezien van de standaard deviatie score (Z- 
score) voor de lengte gedurende de eerste 6-12 maanden van de behandeling. Bij pati­
enten die schedelbestraling kregen wordt een significante verdere daling van de Z-score 
voor lengte gezien gevolgd door een periode van stabiele groeisnelheid waarna bij alle 
patiënten inhaalgroei wordt waargenomen. De niet bestraalde patiënten haalden het 
lengteverlies volledig in, echter bij patiënten die schedelbestraling hebben ondergaan 
wordt een incomplete inhaalgroei gezien.
Er is geen verschil in lengtegroei tussen patiënten die 24 Gy schedelbestraling en pati­
enten die 18 Gy schedelbestraling kregen. Evenmin is er verschil in lengtegroei na be­
handeling volgens een protocol voor de normale risico groep en volgens een hoog risico 
protocol. Er is echter een synergistisch negatief effect op de lengtegroei van hoge dosis 
chemotherapie en schedelbestraling.
In hoofdstuk 3 wordt de lengtegroei beschreven tijdens de fase van onderhoudstherapie. 
Tot 1988 bestond de onderhoudstherapie uit een combinatie van chemotherapie en corti- 
costeroïden. De patiënten die deze onderhoudstherapie kregen, toonden geen inhaalgroei 
tijdens de fase van onderhoudstherapie. In de behandelingsprotocollen na 1988 bestond 
de onderhoudstherapie alleen uit chemotherapie. De verwachting was dat, wanneer 
vooral corticosteroïden een remmende werking hadden op de groei in deze fase van de 
behandeling, er mogelijk wel inhaalgroei zou kunnen optreden bij die patiënten die in 
deze fase van de behandeling alleen chemotherapie kregen.
In de studie die beschreven wordt in hoofdstuk 3 wordt de Z-score voor lengte tijdens 
onderhoudstherapie van 2 groepen prepuberale patiënten vergeleken: één groep kreeg 
chemotherapie en corticosteroïden en de andere groep kreeg alleen chemotherapie tijdens
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onderhoudstherapie. Er wordt geen significant verschil gezien in Z-score voor lengte 
tussen de twee groepen patiënten. De conclusie van dit onderzoek is dat de 
groeiremmende werking van chemotherapie met 6-Mercaptopurine en Methotrexaat 
alleen, gelijk is aan de groeiremmende werking van dezelfde chemotherapie in 
combinatie met corticosteroïden en dat dus minstens ook chemotherapie een 
groeiremmende werking heeft.
In de hoofdstukken 4 en 5 wordt de inhaalgroei beschreven. Na een periode van daling 
van de Z-score voor lengte gevolgd door een periode van constante groeisnelheid, 
vertonen alle patiënten een toename van de Z-score voor lengte, dus inhaalgroei. In 
tegenstelling tot de niet bestraalde patiënten is de inhaalgroei voor bestraalde patiënten 
incompleet en ontstaat er op dit moment lengte verlies dat consequenties heeft voor de 
eindlengte. Door middel van analyse van curves van groeisnelheid, groeiversnelling, Z- 
snelheid  en Z -versnelling  w ordt de invloed van de versch illende  
behandelingsmodaliteiten: chemotherapie, radiotherapie en corticosteroïden op de inhaal- 
groei bestudeerd.
In hoofdstuk 4 wordt de timing en in hoofdstuk 5 de intensiteit van de inhaalgroei 
beschreven. Op het moment van het stellen van de diagnose ALL is de groeisnelheid 
laag. Direct na aanvang van de behandeling wordt een groeiversnelling met een toename 
van de groeisnelheid gezien. Hieruit kunnen wij concluderen dat de ziekte ALL invloed 
heeft op de lengtegroei. Ondanks een toename van de groeisnelheid direct na de start van 
de behandeling met een verdere toename van de groeisnelheid tijdens de hele periode van 
behandeling, wordt een toename van de Z-score voor lengte pas gezien vanaf het moment 
dat de Z-snelheid positief wordt. Hieruit kan geconcludeerd worden dat het moment 
waarop de Z-snelheid positief wordt, het werkelijke begin van de inhaalgroei is. Het 
moment waarop de Z-snelheid positief wordt is voor bestraalde patiënten significant later 
dan voor de niet bestraalde patiënten. Hoewel bij bestraalde patiënten het moment waar­
op de inhaalgroei begint ongeveer gelijk valt met het moment van staken van de therapie, 
kan uit deze studie geconcludeerd worden dat het begin van de inhaalgroei onafhankelijk 
is van het moment van staken van de therapie en dat het samenvallen van deze momenten
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slechts een toevalligheid is. De duur van de inhaalgroei is voor alle patiënten gelijk.
De intensiteit van de inhaalgroei is gedefiniëerd als de afstand tussen de minimale en de 
maximale Z-snelheid. De minimale Z-snelheid van de bestraalde patiënten is significant 
lager dan de minimale Z-snelheid van de niet bestraalde patiënten. De maximale Z- 
snelheid is gelijk voor alle patiënten. Hieruit kan geconcludeerd worden dat de intensiteit 
van de inhaalgroei hoger is bij de bestraalde patiënten.
De bevindingen dat de duur van de inhaalgroei gelijk is voor bestraalde en niet bestraalde 
patiënten en dat de intensiteit van de inhaalgroei groter is bij bestraalde patiënten, terwijl 
toch de uiteindelijke Z-score voor lengte achterblijft, ondersteunen de hypothese dat 
schedelbestraling een beschadiging geeft van het centrale mechanisme dat de normale 
lichaamslengte herkent waarbij het mechanisme wordt afgesteld op een kortere 
lichaamslengte. Er wordt geen verschillende invloed gezien op de inhaalgroei van 
onderhoudstherapie met en zonder corticosteroïden.
In hoofdstuk 6 wordt de lengtegroei beschreven tijdens de fase van de puberteit van 11 
jongens en 17 meisjes. Alle patiënten die in deze studie zijn opgenomen kregen 
schedelbestraling met een dosis van 24 Gy als CZS profylaxe . De leeftijd van deze 
patiënten bij het stellen van de diagnose ALL was <  7 jaar en de leeftijd waarop het 
laatste vervolg onderzoek plaatsvond was >  16 jaar voor de meisjes en >  18 jaar voor 
de jongens. In vergelijking met de referentie populatie treedt bij meisjes het begin van de 
puberteit en de menarche op een jongere leeftijd op en is de duur van de 
puberteitsgroeispurt korter. In vergelijking met meisjes die vroeg in de puberteit komen 
is de groeisnelheid op het moment van Peak Height Velocity lager. Het gevolg hiervan is 
dat de bereikte eindlengte korter is dan verwacht op basis van de SDS voor lengte voor 
de start van de puberteit. Bij jongens is de duur van de puberteitsgroeispurt korter en de 
lengtewinst tijdens de puberteitsgroeispurt minder dan in de referentie populatie. Bij 
beide sexen is de ontwikkeling van de botrijpheid versneld.
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In hoofdstuk 7 wordt een longitudinale studie beschreven naar gewicht naar lengte van 
92 patiënten. Vierenvijftig patiënten kregen schedelbestraling met een dosis van 18 of 24 
Gy en 38 patiënten werden niet bestraald. Zevenenzeventig patiënten werden behandeld 
met chemotherapie volgens een normaal risico protocol en 15 patiënten kregen een 
intensievere behandeling met chemotherapie volgens een hoog risico protocol. Bij de 
meeste bestraalde patiënten was de follow-up duur 12 jaar en voor de niet bestraalde 
patienten 4,5 jaar. Dertig van de 92 patiënten werden behandeld volgens een protocol 
zonder schedelbestraling maar met een verschil in het gebruik van corticosteroïden: 19 
patiënten kregen dexamethason tijdens de remissie-inductie en onderhoudsbehandeling en 
11 patiënten kregen prednison. De invloed van dexamethason versus prednison, 
schedelbestraling en hoge dosis versus lage dosis chemotherapie op gewicht naar lengte 
wordt geanalyseerd.
Patiënten die dexamethason kregen ontwikkelen een significante toename van gewicht 
naar lengte direct na de start van de behandeling. Bij patiënten die schedelbestraling 
kregen neemt het gewicht naar lengte significant toe na het eerste jaar van de 
behandeling. Het overgewicht van deze patiënten blijft tijdens de hele periode van 
follow-up bestaan. Het gewicht naar lengte van patiënten die behandeld werden met 
prednison en van patiënten die niet bestraald werden is tijdens de behandeling onder het 
gemiddelde gewicht van de normale populatie en normaliseert na het staken van de 
therapie. Er is geen verschil in toename van gewicht tussen jongens en meisjes en tussen 
patiënten die behandeld werden volgens hoog of normaal risico protocol.
In hoofdstuk 8 volgt een algemene discussie over de conclusies van het onderzoek. De 
verschillende factoren die een invloed uitoefenen op de lengtegroei zijn: de ziekte ALL, 
de drie behandelingsmodaliteiten: chemotherapie, schedelbestraling en corticosteroïden 
en een slechte voedingstoestand van de patiënt. ALL heeft een negatieve invloed op de 
lengtegroei tijdens de vroege fase van de behandeling waarschijnlijk tot het moment dat 
complete remissie is bereikt. Tijdens de eerste zes maanden van de behandeling hebben 
chemotherapie en corticosteroïden een groeiremmend effect. Chemotherapie heeft een 
remmende werking op de inhaalgroei tijdens de fase van onderhoudstherapie. Wanneer
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de behandeling bestaat uit hoge dosis chemotherapie en schedelbestraling wordt er van 
beide factoren een synergistisch negatief effect op de groei gezien. Het groeiremmend 
effect van schedelbestraling treedt op verschillende momenten van de groei op. 
Gedurende het eerste jaar van de behandeling treedt er een grotere groeiachterstand op 
dan bij patiënten die geen schedelbestraling kregen. De inhaalgroei van deze patiënten is 
niet compleet. Bij meisjes begint de puberteit op een jongere leeftijd. De 
puberteitsgroeispurt van zowel jongens als meisjes verloopt niet optimaal. In de eerste 
drie maanden van de behandeling hebben alle patiënten, met uitzondering van patiënten 
die dexamethason kregen, ondergewicht. Gedurende deze periode kan ondergewicht een 
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150
Woorden van dank
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beroep op je  doen. De verzorging van de lay-out heb je volledig voor jouw rekening 
genomen. Zo is dit proefschrift een gezamenlijk project geworden. Dank je  wel voor alle 
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